Mesenchymal Stem/Stromal Cell-Derived Exosomes for Immunomodulatory Therapeutics and Skin Regeneration

Dae Hyun Ha 1,†, Hyun-keun Kim 1,†, Joon Lee 2, Hyuck Hoon Kwon 3, Gyeong-Hun Park 4, Steve Hoseong Yang 5, Jae Yoon Jung 6, Hosung Choi 7, Jun Ho Lee 1, Sumi Sung 1, Yong Weon Yi 1,* and Byong Seung Cho 1,*

1 ExoCoBio Exosome Institute (EEI), ExoCoBio Inc., Seoul 08594, Korea; dh.ha@exocobio.com (D.H.H.); hyunkeun.kim@exocobio.com (H.-k.K.); junho.lee@exocobio.com (J.H.L.); sumi.sung@exocobio.com (S.S.)
2 School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Korea; purequill@naver.com
3 Oaro Dermatology Clinic, Seoul 13620, Korea; banbury@hanmail.net
4 Department of Dermatology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwasweong-si, Gyeonggi-do 18450, Korea; jin66666@hanmail.net
5 Guam Dermatology Institute, Tamuning, GU 96913, USA; guamderm@gmail.com
6 Oaro Dermatology Clinic, Seoul 01695, Korea; jaeyoon007@hanmail.net
7 Piena Clinic, Seoul 06120, Korea; hosungee@naver.com
* Correspondence: yongweon.yi@exocobio.com (Y.W.Y.); ceo@exocobio.com (B.S.C.);
† These authors contributed equally to this article.

Received: 20 February 2020; Accepted: 4 May 2020; Published: 7 May 2020

Abstract: Exosomes are nano-sized vesicles that serve as mediators for cell-to-cell communication. With their unique nucleic acids, proteins, and lipids cargo compositions that reflect the characteristics of producer cells, exosomes can be utilized as cell-free therapeutics. Among exosomes derived from various cellular origins, mesenchymal stem cell-derived exosomes (MSC-exosomes) have gained great attention due to their immunomodulatory and regenerative functions. Indeed, many studies have shown anti-inflammatory, anti-aging and wound healing effects of MSC-exosomes in various in vitro and in vivo models. In addition, recent advances in the field of exosome biology have enabled development of specific guidelines and quality control methods, which will ultimately lead to clinical application of exosomes. This review highlights recent studies that investigate therapeutic potential of MSC-exosomes and relevant mode of actions for skin diseases, as well as quality control measures required for development of exosome-derived therapeutics.

Keywords: anti-aging; anti-inflammation; hair growth; immunomodulation; mesenchymal stem cells (MSCs); MSC-exosomes; skin barrier; therapeutics; regenerative aesthetics; wound healing

1. Introduction

The discovery of extracellular vesicles (EVs) or exosomes goes back to the 1940s, and these tiny vesicles were ignored as cellular garbage bins for a long time [1–3]. They only began to draw significant attention around the mid-2000s after re-discovery of exosomes as messengers for cell-to-cell communications [1,4–6]. It is no exaggeration to say that we are at the dawn of the exosome era. There were more than three thousand publications on EVs or exosomes and related subjects in PubMed annually in 2018 and 2019 [1]. The race toward commercialization of exosome-based therapeutics has already begun [7–10]. The top four exosome start-up companies, Codiak Biosciences, Exosome...
Diagnostics, Evox Therapeutics, and ExoCoBio have received approximately $386.2 million in investor funding [8]. In addition, several big deals have been made between exosome start-ups and big pharma companies [10].

Exosomes are nano-sized extracellular vesicles (EVs) released by almost all eukaryotic cells [11]. In general, their size ranges from 30 nM to 200 nM. Two other subpopulations of EVs are microvesicles (100–1000 nM) and apoptotic bodies (500–2000 nM) [12–14]. Exosomes derived from stem cells have attractive therapeutic potential in several aspects [15]. It has been established that the mode of action (MoA) for therapeutic effects of stem cells is mainly paracrine effects mediated by secreted factors from stem cells [6,16]. Among parts of the secretome of stem cells, exosomes have been reported to play the major role in the paracrine effects [16–18]. Mesenchymal stem/stromal cells (MSCs) are the most preferable source of therapeutic exosomes, since MSCs themselves appear to be safe based on huge amount of clinical data over the last decade [15]. In addition, MSC-derived exosomes (MSC-exosomes) can be sterilized by filtration and produced as an off-the-shelf product, while MSCs themselves cannot. Moreover, MSC-exosomes are considered to be free from the safety issues in the context of cell-based therapy, such as tumorigenic potential by cell administration [19,20]. Indeed, MSC-exosomes have been applied as alternatives to MSCs for new cell-free therapeutic strategies in a variety of disease models including neurological, cardiovascular, immune, renal, musculoskeletal, liver, respiratory, eye, and skin diseases, as well as cancers [15,17,19,21,22].

2. MSCs as Sources of Exosomes

MSCs have both self-renewal capabilities (i.e., they can generate more MSCs themselves) and differentiation (into other types of cells) potentials [23]. MSCs can be obtained from a range of tissues and body fluids, such as adipose tissue, bone marrow (BM), dental pulp, synovial fluid (SF), amniotic fluid (AF), placenta (PL), umbilical cord (UC), umbilical cord blood (UCB), and Wharton’s jelly (WJ) [24]. MSCs can also be derived from embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) [25–27]. MSCs, depending on their origins, are able to differentiate into diverse types of cells including adipocytes, chondrocytes, osteoblasts, and myocytes [28]. In addition, MSCs have immunomodulatory properties to regulate various cells involved in immune responses, such as dendritic cells (DCs), lymphocytes, macrophages, mast cells, neutrophils, and natural killer (NK) cells [24]. On these bases, MSCs have been spotlighted as potent cell therapeutics for various diseases over the last decades.

In the reported preclinical studies of MSC-exosomes, MSCs were isolated from various tissues/cells in the following order: BM (51%), umbilical/placental tissues (23%), adipose tissue (13%), derived from ESCs or iPSCs (8%), and others (5%) [29]. Since characteristics and functionality of MSCs depend on their origins, it is obvious that those of MSC-exosomes vary according to the origin of MSCs. However, comparative studies of MSC-exosomes by their tissue origin are still limited, and only a few reports have compared different MSC-exosomes within the same study (Table 1) [30–35]: (1) human adipose tissue-derived MSC (ASC)-exosomes exhibited a higher activity of neprilysin, an amyloid β (Aβ) peptide degrading enzyme in the brain, than human bone marrow MSC (BM-MSC)-exosomes, suggesting the therapeutic relevance of ASC-exosomes in Alzheimer’s disease [30]; (2) human BM-MSC-EVs and Wharton’s jelly MSC (WJ-MSC)-EVs decreased cell proliferation and induced apoptosis, while ASC-EVs increased cell proliferation and had no apoptotic effect in U87MG glioblastoma cells [31]. However, the effects of MSC-exosomes on cancer cells are controversial [36]. For example, ASC-exosomes have been reported to have anti-cancer activity on prostate cancer both in vitro and in vivo [37]; (3) human menstrual fluid MSC (MenSC)-exosomes and BM-MSC-exosomes promoted neurite growth both in cortical and sensory neurons, while human chorion MSC-exosomes and UC-MSC-exosomes did not. This suggests that appropriate selection of MSC sources might be essential for the treatment of neurodegenerative diseases [32]; (4) human iPSC MSC (iMSC)-exosomes and synovial membrane MSC (SM-MSC)-exosomes both attenuated osteoarthritis (OA) in a murine model, but iMSC-exosomes had a superior therapeutic effect compared to SM-MSC-exosomes [33]; (5) a study comparing
canine MSCs reported that BM-MSCs released a higher level of secretome, including exosomes, than ASCs did [34]; and (6) human amniotic fluid MSCs (AF-MSCs) released a higher amount of exosomes than BM-MSCs [35]. However, it is difficult to directly compare the results between the above studies, since they were not performed with comparable processes or methods for isolation, characterization, and efficacy evaluation for exosomes. In addition, variations from different donors or preparation methods for MSCs remain a prominent challenge [38,39]. Nevertheless, it is suggested that MSC-exosomes might exhibit different properties and efficacies depending on the origin of MSCs. Therefore, biological differences such as the origin of MSCs and efficacy of their exosomes should be considered for specific clinical applications.
Table 1. Mesenchymal stem cell (MSC)-exosomes from different sources.

| Diseases/Focuses          | Nomenclature | Exosome Isolation       | MSC Origin                  | Outcome                                                                 | Reference |
|---------------------------|--------------|-------------------------|-----------------------------|-------------------------------------------------------------------------|-----------|
| Alzheimer’s disease       | Exosomes     | Ultracentrifugation     | Human adipose tissue        | Adipose stem cell (ASC)-exosomes had superior effects compared to bone marrow (BM)-MSC-exosomes | [30]      |
|                           |              |                         | Human bone marrow           | Decreased Aβ peptide in the N2a cells                                   |           |
| Glioblastoma              | Extracellular Vesicles (EVs) | Ultrafiltration     | Human bone marrow           | Decreased U87MG cell proliferation                                       | [31]      |
|                           |              |                         | Human Wharton’s jelly       | Induced apoptosis in the U87MG cells                                    |           |
|                           |              |                         | Human adipose tissue        | Increased U87MG cell proliferation                                       |           |
|                           |              |                         | Human Wharton’s jelly       | No apoptotic effect                                                     |           |
| Neurodegenerative disease | Exosomes     | Ultracentrifugation     | Human menstrual fluid       | Promoted neurite outgrowth in cortical and sensory neurons              | [32]      |
|                           |              |                         | Human bone marrow           | No effect                                                               |           |
|                           |              |                         | Human chorion               |                                                                           |           |
|                           |              |                         | Human umbilical cord        |                                                                           |           |
| Osteoarthritis (OA)       | Exosomes     | Ultrafiltration         | Human iPSCs                 | Attenuated OA in a murine model                                          | [33]      |
|                           |              |                         | Human synovial membrane     | Stimulated chondrocyte migration and proliferation                       |           |
|                           |              |                         |                             | Induced pluripotent stem cell-derived MSC (iMSC)-exosomes exert superior therapeutic effects compared to synovial membrane (SM)-MSC-exosomes |           |
| Exosome release           | Exosomes     | Ultracentrifugation     | Canine bone marrow          | BM-MSCs released higher amount of exosome compared to ASCs              | [34]      |
|                           |              |                         | Canine adipose tissue       |                                                                           |           |
|                           | Exosomes     | Total Exosome Isolation Kit (Invitrogen) | Human amniotic fluid | Amniotic fluid (AF)-MSCs released higher amount of exosome compared to BM-MSCs | [35]      |
|                           |              |                         | Human bone marrow           |                                                                           |           |

**Abbreviations**: AF, amniotic fluid; ASC, adipose stem cell; BM, bone marrow; EVs, extracellular vesicles; iMSC, induced pluripotent stem cell-derived MSC; OA, osteoarthritis.
3. Quality Control of EVs for Development of Therapeutic EVs

It is of importance to manufacture clinical-grade EVs with a good manufacturing practice (GMP)-compliant process and quality control (QC) for the development of EV-based therapeutics [40–42]. Appropriate QC is also crucial for reproducible studies in academic settings. Recently, the International Society for Extracellular Vesicles (ISEV) proposed a series of the Minimal Information for Studies of Extracellular Vesicles (MISEV), finalized as MISEV2018 [43–45]. The Korea Ministry of Food and Drug Safety (MFDS) published the world’s first guideline for EV therapy products, entitled the Guideline on Quality, Non-clinical, and Clinical Assessment of Extracellular Vesicles Therapy Products [46]. As shown in Table 2, most of the criteria in these guidelines are similar [1] and have been already been applied in GMP settings [42,47,48]. Routine QC criteria include the determination of the quantity, size, identity, and purity of EVs.

Table 2. Quality control (QC) criteria in the guidelines and good manufacturing practice (GMP) settings.

| QC Criteria | Examples in Guidelines | Examples in GMP Settings |
|-------------|------------------------|-------------------------|
| Exosome Quantity | ISEV Recommendation [43–45] | MFDS Guideline (2018) [46] | Pachler et al. [47] | Andriolo et al. [48] | Mendt et al. [42] |
| Exosome Size | NTA ¹ | NTA ¹ | - | - | - |
| Identity | Proteins | Lipids | (WB: CD9, CD81, TSG101) | (FCM: CD9, CD63, CD81 ELISA: TSG101) | (FCM: CD47, CD63, CD81, CD9, CD29, CD90) |
| Parity | Proteins that are expected not to be enriched in exosomes | Proteins that are expected not to be enriched in exosomes | (WB: GM130) | - | - |
| Process impurities depending on the source of exosomes | Process impurities (serum albumin, antibiotics, etc.) | - | - | - | - |
| Potency Assays | Dose-response assessment | Biological assay, which can represent MoA | - | Anti-apoptotic activity; Pro-angiogenic activity | Apoptosis assay |
Table 2. Cont.

| QC Criteria                  | Examples in Guidelines | Examples in GMP Settings |
|-----------------------------|------------------------|-------------------------|
| ISEV Recommendation [43–45] | MFDS Guideline (2018) [46] | Pachler et al. [47]      |
|                             |                        | Andriolo et al. [48]     |
|                             |                        | Mendt et al. [42]        |
| Mycoplasma test             | -                      | -                       |
| Sterility test              | -                      | Microbiological Control  |
|                            |                        | for Cellular Products    |
| Endotoxin test              | -                      | Quantitative LAL test    |
| Adventitious virus test      | -                      | -                       |

1 Since these methods cannot differentiate EVs from non-EV particles, it is recommended to compare results from these methods with results from TEM, AFM, or other microscopic observation. 2 Comparison with results from quantification methods such as protein quantification is also recommended. **Abbreviations**: AF4, multi-angle light scattering coupled to asymmetric flow field-flow fractionation; AFM, atomic force microscopy; DLS, dynamic light scattering; FCM, flow cytometry; FCS, fluorescence correlation spectroscopy; ISEV, International Society for Extracellular Vesicles; LAL, limulus amebocyte lysate; MoA, mode of action; MFDS, Ministry of Food and Drug Safety; NTA, nanoparticle tracking analysis; RPS, resistive pulse sensing; WB, Western blotting.

3.1. EV Quantity and Size

Both the MISEV2018 and the MFDS guidelines recommend using at least two different methods for determining the quantity of EVs [45,46]. Quantification of EVs can be achieved by measuring the total amounts of proteins, lipids, or RNAs, since EVs consist of all these molecules. These methods, however, do not provide the information on the number of EV particles. Several methods are available to measure the number and size of particles, including nanoparticle tracking analysis (NTA), resistive pulse sensing (RPS), and dynamic light scattering (DLS). The most widely used method is NTA [42,47–53]. NTA determines the number and size of particles by tracking the Brownian motion of single particles in an aqueous solution [54]. However, NTA suffers from a low resolution of poly-dispersed samples and high variations, such as inter-device, inter-assay, and intra- and inter-individual variations [55–57]. In addition, NTA does not differentiate EVs from other nanoparticles such as protein aggregates. Recently, instruments for fluorescence NTA have been introduced to detect fluorescently labeled EVs with specific antibodies [58]. Quantification of EVs, however, remains extremely challenging. New technologies and instruments have been introduced annually, especially during the ISEV conference, such as nano flow cytometry [59,60], direct stochastic optical reconstruction microscopy [61], ExoCounter with the optical disc technology [62], and imaging flow cytometry [63]. Although it will take some time to develop fully GMP-compatible instruments, the great strides forward in methodologies for the quantification of EVs are expected to result in the overcoming of current hurdles in the near future.

3.2. EV Identity

A variety of proteins have been reported to be associated with EV, especially exosomes, including tetraspanins (CD9, CD63, and CD81), Annexins, Flotillin, ALG-2-interacting protein X (Alix), and tumor susceptibility gene 101 (TSG101) protein [45,64]. Proteins such as CD9, CD63, CD81, TSG101, and Alix are recommended as specific markers for exosomes since they are known to be highly enriched in exosomes compared to the originating cells [45,64–66]. In addition, because Alix and TSG101 are involved in the formation of multivesicular bodies (MVBs), presence of these proteins is essential to support the endocytic origin of exosomes [43,45,64]. For QC, at least semi-quantitative methods are recommended to detect these proteins in exosomes [46]. The enzyme-linked immunosorbent assay (ELISA) and flow cytometric analysis are each suitable for both GMP-compliant facilities and general academic labs. Although Western blotting has been widely used in the academic labs, this method is limited by lack of appropriate quantification and method validation [67].

3.3. EV Purity

Purity of EVs is also a critical criterion for QC. A simple method to monitor purity of EVs is to determine the particle-to-protein, protein-to-lipid, or RNA-to-particle ratios [45]. The absence of
intracellular proteins, such as histones, lamin A/C, GRP94 (i.e., HSP90B1), GM130 (i.e., GOLGA2), and cytochrome C (i.e., CYC1), is another important criterion to determine the purity of EVs or exosomes, since these proteins are not enriched in exosomes due to their strict cellular localization [43,45]. Impurities from cell culture process including antibiotics and serum should also be analyzed to monitor the removal of potential hazardous substances [46]. Every batch of EVs should be qualified by routine QC before being used for therapeutic purposes or functional assays, even in the academic labs, to ensure reproducibility.

3.4. Potency Assays

Potency assays are the most important QC criterion to predict efficacy of EVs in vivo. Regulatory authorities such as the US Food and Drug Administration (FDA) recommend using appropriate potency tests for cellular and gene therapy products [68]. The MISEV2018 and the MFDS guidelines also recommend including potency assays for EV QC [45,46]. Potency is defined as “the specific ability or capacity of the product, as indicated by appropriate laboratory tests or by adequately controlled clinical data obtained through the administration of the product in the manner intended, to effect a given result” [68]. Many biological and biochemical assays have been reported to demonstrate the potency of EVs or exosomes [69,70]. Since quantification of EVs remains challenging, establishment of an appropriate potency assay would be an invaluable tool to monitor batch-to-batch consistency and determine the dose of EVs [71]. Although ideal potency assays should represent the MoA, it is difficult to set-up an appropriate potency assay with single biochemical or isolated cell-based assays due to the difficulty in the identification of single bioactive substances in the complex cargo of EVs. As an example, it is hard to mimic the complex immune responses in vivo with in vitro cell-based assays [70–73].

4. Anti-Inflammation and Immunomodulation by MSC-Exosomes

Immune cells secrete soluble factors such as inflammatory cytokines and mediators, which can contribute in the event of inflammation [74,75]. In particular, pro-inflammatory cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-1β, are mainly produced by activated macrophages. These cytokines play important roles in the upregulation of inflammatory responses such as activation of macrophages and recruitment of additional immune cells [74,75]. In contrast, anti-inflammatory cytokines are produced by regulatory T cells (Tregs), helper T (Th)2 cells, alternatively activated macrophages, and monocytes, which control the inflammatory responses and immunity [75,76]. Major anti-inflammatory cytokines include IL-1 receptor agonist (IL-1RA), IL-4, IL-10, and transforming growth factor (TGF)-β [76]. These cytokines inhibit the Th1 responses and production of pro-inflammatory cytokines [76].

Inflammation is a mechanism of innate immunity in response to harmful stimuli, including pathogens, damaged cells, or irritants, and typically manifests as heat, pain, redness, swelling, and loss of function [77]. Uncontrolled chronic inflammatory responses are associated with diverse inflammatory diseases such as allergy, asthma, autoimmune diseases, inflammatory bowel disease (IBD), OA, atherosclerosis, and hepatitis [77–79]. In addition, many scientists now consider inflammation as the root cause of most chronic diseases such as heart attacks, strokes, type 2 diabetes, Alzheimer’s disease, and even cancer [80,81]. Therefore, regulation of inflammation is an important therapeutic target to treat inflammatory diseases. It has been demonstrated that MSCs have property of intrinsic immunosuppressive capabilities to alleviate inflammation and immune responses [82]. MSC-exosomes can be an excellent alternative to MSC cell therapy since MSC-exosomes possess similar biological functions to the originating cells, while they are more stable and have lower immunogenicity compared to their originating cells [83]. In fact, anti-inflammatory and immunomodulatory functions of MSC-exosomes have been extensively reported (Table 3) [21,84–151].
| Category | Exosome Source                  | Nomenclature       | Exosome Isolation | Related Exosomal Cargo | Secreted Factors or Expressed Genes Affected | Immunomodulatory Effects                                                                 | Reference |
|----------|--------------------------------|--------------------|-------------------|------------------------|---------------------------------------------|--------------------------------------------------------------------------------------------|-----------|
|          | Human jaw bone marrow (JM-MSCs) | Human JM-MSCs      | Exosomes          | Ultracentrifugation    | miR-223                                     | TNF-α ↓ IL-10 ↑ Accelerated wound healing in mice Induced M2 macrophage polarization (CD206↑ macrophage ↑) | [85]      |
|          | Human BM-MSCs                   | Human BM-MSCs      | Exosomes          | Ultracentrifugation    | -                                           | Collagen, IL-6, Ccl2, Cxcl6, Cxcl7, Ccl7, Tnfa, Retn, Arg1 ↑ Reduced BPD through macrophage M22 polarization | [86]      |
|          | Human umbilical cord (UC)-MSCs  | Human UC-MSCs      | Exosomes          | Ultracentrifugation    | let-7b                                       | TLR4, p-p65, iNos ↓ p-STAT3, p-AKT, Arg1 ↑ Alleviated inflammation and enhanced diabetic cutaneous wound healing in rats Induced M2 macrophage polarization Inhibited TLR4 signaling pathway | [87]      |
|          | Human menstrual blood derived MSCs (MenSCs) | Human MenSCs | Exosomes          | Ultracentrifugation    | -                                           | Inos ↓ ARG1, VEGF ↑ Resolved inflammation and ameliorate cutaneous non-healing wounds in diabetic mice Induced M2 macrophage polarization | [89]      |
|          | Mouse BM-MSCs                   | Mouse BM-MSCs      | Exosomes          | HPLC                   | let-7                                         | HMGA2, IGF2BP1 ↓ Attenuated atherosclerosis in mice Reduced area of atherosclerotic plaques Promoted M2 macrophage polarization | [90]      |
|          | Mouse BM-MSCs                   | Mouse BM-MSCs      | Exosomes          | Ultracentrifugation    | miR-182                                      | IL-6, iNos, IL-1β, IL-6, TNF-α ↓ ARG1, IL-10, TGF-β ↑ Reduced myocardial ischemic-reperfusion injury in mice Reduced infarct size and inflammation Promoted M2 macrophage polarization | [91]      |
|          | Human BM-MSCs                   | Human BM-MSCs      | Exosomes          | Ultracentrifugation    | MT2A                                         | IFN-γ, IL-1β, IL-6, TNF-α ↓ IL-10, Ly61, Def620, Def629, Arg1 ↑ Reduced IBD by polarizing M2 macrophage in mice | [92]      |
|          | Rat ASCs                        | Rat ASCs           | Exosomes          | Ultracentrifugation    | -                                            | SIP, SphK1, S1PR1 ↑ AGR1, Ym1, TGF-β1, IL-10 ↑ IL-1β, IL-6, TNF-α, IFN-γ, p65 ↓ Reduced cardiac damage in rats Reduced fibrosis and apoptosis Promoted M2 macrophage polarization | [93]      |
|          | Human ASCs                      | Human ASCs         | Exosome isolation | Exosome Isolation Kit | -                                            | CD163, ARG1, CD206, STAT6, MacB ↑ Increased the expression of M2 macrophage markers | [94]      |
|          | Mouse ASCs                      | Mouse ASCs         | Exosomes          | Ultrafiltration        | STAT3                                         | ARG1, IL-10, tyrosine hydroxylase ↑ TNF-α, IL-12 ↓ Induced M2 macrophage polarization in obese mice ASC-exosome-educated M2 macrophage promoted WAT beiging | [95]      |
### Table 3. Cont.

| Category | Exosome Source | Nomenclature | Exosome Isolation | Related Exosomal Cargo | Secreted Factors or Expressed Genes Affected | Immunomodulatory Effects | Reference |
|----------|---------------|--------------|-------------------|------------------------|--------------------------------------------|--------------------------|-----------|
| T cell regulation | Human BM-MSCs | Exosomes | ExoQuick (System Biosciences) | - | TNF-α, IL-1β ↓ TGF-β ↑ | Induced conversion of Th1 into Th2 | [96] |
| | Human BM-MSCs | Exosomes | Ultracentrifugation | - | IL-10, TGF-β ↑ | Promoted proliferation and immune-suppression capacity of Tregs | [97] |
| | Human UC-MSCs | Exosomes | PEG6000 precipitation | - | IL-10, IDO ↑ | Induced an increase of Tregs in PBMCs Inhibited proliferation of PBMCs | [98] |
| | Human embryonic stem cell (ES)-MSCs | Exosomes | Tangential flow filtration + HPLC | EDA-FN | TNF-α, IL-1β, IL-6, IL-12p40 ↓ IL-10 ↑ | Induced Tregs through activation of APCs in the MyD88-dependent manner Enhanced allogeneic skin graft | [99] |
| | Mouse ASCs | Exosomes | Ultracentrifugation | - | IL-17, IFN-γ ↓ IL-4, IL-10, TGF-β ↑ | Ameliorated autoimmune type 1 diabetes mellitus by increasing Tregs in mice | [100] |
| | Human BM-MSCs | Exosomes | Ultracentrifugation | - | IL-6, IL-12p70, IL-22, IL-17AF ↓ | Improved motor skill in the MS mouse experimental autoimmune encephalomyelitis model Increased Tregs and decreased infiltration and proliferation of pro-inflammatory T cells | [101] |
| | Mouse BM-MSCs | Exosomes | Ultracentrifugation | - | IL-1, IL-2, IL-4, IL-10, TNF-α, IFN-γ ↓ | Decreased aminotransferase (ALT), liver necrotic areas, and apoptosis in Con A-induced liver injury in mice Increased Tregs | [102] |
| | UC-MSCs | EVs | Size exclusion chromatography | - | - | Suppressed T cell proliferation | [105] |
| B cell regulation | Human BM-MSCs | Exosomes | Ultracentrifugation | - | MZB1, CXCL8 ↑ IgM ↓ | Reduced proliferation of T and B cells | [106] |
| Photoaging | Human BM-MSCs | Exosomes | Ultrafiltration | - | TNF-α, IL-1β ↓ TGF-β, CTLA4 ↑ | Reduced photosaging of skin in mice Ameliorated inflammation | [107] |
| Skin flap | Human ASCs | Exosomes | Ultracentrifugation | - | - | Enhanced neovascularization and survival of the skin flap in rats Reduced inflammation and apoptosis | [108] |
| Atopic dermatitis (AD) | Human ASCs | Exosomes | Tangential flow filtration | - | IgE, IL-4, IL-5, IL-13, IL-17, IL-23, IL-31, IFN-γ, TNF-α, TSLP ↓ | Reduced pathological symptoms of AD in mice Reduced mast cell infiltration Reduced inflammatory dendritic epidermal cells (CD38+/CD206+ cells) | [20,109] |
Table 3. Cont.

| Category | Exosome Source | Nomenclature | Exosome Isolation | Related Exosomal Cargo | Secreted Factors or Expressed Genes Affected | Immunomodulatory Effects | Reference |
|----------|----------------|--------------|-------------------|------------------------|---------------------------------------------|--------------------------|-----------|
| Renal injury | Rat BM-MSCs | Exosomes | Ultracentrifugation | - | MDA, HIF1α, NOX2, Caspase 3, BAX, PARP1, MPO, ICAM1, IL-1β, NF-κB ↓ SOD, CAT, GPX, HO-1, BCL2, IL-10, bFGF, HGF, SOD, VEGF ↑ | Decreased histopathological score of kidney injury in rats Reduced the levels of blood urea nitrogen (BUN) and creatinine Reduced the level of oxidative stress Increased anti-oxidant status Reduced apoptosis and inflammation Improved regeneration and enhanced angiogenesis | [110] |
| | Mouse BM-MSCs | Exosomes | Ultracentrifugation | CCR2 | TNF-α, IL-6, IL-1β ↓ | Reduced BUN and creatinine in the mouse IR model Reduced infiltration of macrophages | [111] |
| | Human UC-MSCs | Exosomes | Ultracentrifugation | - | PCNA, BCL-XL, BCL2, IL-1β, 4E-BP1 ↑ Bax, cytochrome C, Caspase-3, p65, TNF-α, IL-6, IL-1β, p-mTOR ↓ | Reduced cisplatin-induced AKI in rats Reduced BUN and creatinine | [112] |
| Uveitis | Human UC-MSCs | Exosomes | Ultracentrifugation | - | - | Reduced experimental autoimmune uveitis in rats Reduced infiltration of Gr-1+, CD161+, CD68+ and CD4+ cells in retina | [113] |
| Duchenne muscular dystrophy (DMD) | Human Placenta MSCs | Exosomes | Ultracentrifugation | miR-29c | TGF-β, creatine kinase, collagen I, collagen IV, TNF-α, IL-6 ↓ Utrophin ↑ | Reduced DMD in mice Decreased the tissue fibrosis and inflammation | [114] |
| Bronchopulmonary dysplasia (BPD) | Human UC-MSCs | Exosomes | Ultracentrifugation | TSG-6 | Neutrophil ↓ | Improved pathology of lung, cardiac and brain in neonatal mice with BPD Reduced pulmonary inflammation and alveolar-capillary leak | [115] |
| Alzheimer’s disease | Mouse BM-MSCs | Exosomes | Ultracentrifugation | - | TNF-α, IL-1β, IL-6 ↓ IL-10, IL-4, IL-13 ↑ | Improved cognitive function in transgenic APP/PS1 mice Reduced plaque deposition and Aβ levels Reduced activation of astrocytes | [116] |
| Post-stroke neuroregeneration | Human BM-MSCs | EVs | PEG6000 precipitation | - | Dcx, NeuN, CD31 ↑ | Improved neurological impairment (motor coordination) and long-term neuroprotection (neuronal survival and cell proliferation) in stroke mice Reduced post-ischemic immunosuppression and lymphopenia Stimulated post-ischemic neurogenesis and angiogenesis | [117] |
Table 3. Cont.

| Category                        | Exosome Source | Nomenclature       | Exosome Isolation | Related Exosomal Cargo | Secreted Factors or Expressed Genes Affected | Immunomodulatory Effects                                                                 | Reference |
|---------------------------------|----------------|--------------------|-------------------|------------------------|---------------------------------------------|-----------------------------------------------------------------------------------------|-----------|
| Diabetic peripheral neuropathy  | Mouse BM-MSCs  | Exosomes           | Ultracentrifugation| miR-17, miR-23a, miR-125b | TNF-α, IL-1β, iNOS, TLR4, IRAK1, p65 ↓ ARG1, IL-10, TGF-β ↑ | Decreased the threshold for thermal and mechanical stimuli in mice Increased nerve conduction velocity, the number of intraepidermal nerve fibers, myelin thickness, and axonal diameters | [118]     |
| OA                              | Rabbit BM-MSCs | Exosomes           | Ultracentrifugation| -                      | p-p38, p-ERK ↓ p-AKT ↑                       | Increased chondrocytes viability under IL-1β-induced inflammatory status through activating AKT pathway | [119]     |
| Human ES-MSCs                   | Human BM-MSCs  | Exosomes           | Tangential flow filtration | CD73, α-SMA, MMP-13, IL-1β, iNOS ↓ PCNA, s-GAG ↑ | PTGS, Bcl-2, IL-6, TNF-α, IL-8, IL-1β ↓ Bax, caspase-3 ↑ | Promoted repair and regeneration of temporomandibular joint OA in rats through the AKT/ERK/AMPK-dependent manner | [120]     |
| Human ES-MSCs                   | Human BM-MSCs  | Exosomes           | ExoQuick (System Biosciences) | miR-26a-5p | TNF-α, IL-1β ↓ PCNA ↑ | Alleviated OA damage in rats treated with pentobarbital | [121]     |
| Intervertebral disc degeneration (IVDD) | Mouse BM-MSCs  | Exosomes           | Ultrafiltration | - | Caspase-9/3, iNOS, MMP-3/13, caspase-1, IL-1β, TXNIP, NLRP3 ↓ COL2A, SOX9 ↑ | Prevented progression of IVDD in rabbit Suppressed activation of NLRP3 inflammasome | [122]     |
| Human UC-MSCs                   | Human UC-MSCs  | EVs                | Ultracentrifugation | IL-1β, IL-6 ↓ | | Demonstrated anti-inflammatory and anti-scarring activities in the spinal cord parenchyma in rats | [123]     |
| Spinal cord injury              | Rat BM-MSCs    | Exosomes           | Ultracentrifugation | - | C3, GFAP, TNF-α, IL-1α, IL-1β, p-p65, p-IκBα ↓ | Reduced spinal cord injury-induced A1 astocytes in rats | [124]     |
| BM-MSCs                         | BM-MSCs        | Exosomes           | Ultrafiltration | - | NO, Bax, caspase-3, TNF-α, IL-1β, IL-6 ↓ Bcl2, VEGF, NF200 ↑ | Improved functional behavioral recovery in rats Attenuated neuronal cells apoptosis, suppressed glial scar formation Suppressed activation of microglia, A1 neurotoxic reactive astocytes and neuroinflammation | [125]     |
| Category                              | Exosome Source         | Nomenclature                     | Exosome Isolation                  | Related Exosomal Cargo                  | Secreted Factors or Expressed Genes Affected                                                                 | Immunomodulatory Effects                                                                 | Reference |
|---------------------------------------|------------------------|----------------------------------|------------------------------------|----------------------------------------|-----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-----------|
| **Myocardial infarction**             | Rat BM-MSCs Exosomes   | -                                | Exosome Isolation Kit (Invitrogen) | miR-29, miR-24                         | -                                                                                                         | Inhibited cardiac fibrosis, inflammation, and improved cardiac function in rat myocardial infarction model | [127]     |
|                                       | Rat BM-MSCs Exosomes   | ExoQuick (System Biosciences)    | -                                 | NO, Bax, caspase-3/9 ↓ Bcl2 ↑          | Improved myocardial in rats through angiogenesis and anti-inflammation                                       |                                                                                           | [128]     |
|                                       | Rat BM-MSCs Exosomes   | Exosome extractant (Ribobio Co., Ltd.) | miR-124-3p | P2X7, TNF-α, IL-6, IL-8 ↓ GSH, SOD ↑ | Increased survival rate of rats                                                                       |                                                                                           | [129]     |
| **Acute lung injury (ALI)**           | Rat BM-MSCs Exosomes   | Ultracentrifugation              | -                                 | TNF-α, IL-1β, IL-6, MMP-9 ↓ IL-10, SP-C ↑ | Attenuated phosphogluconate-induced ALI in rats                                                           |                                                                                           | [130]     |
|                                       | Rat BM-MSCs Exosomes   | Ultracentrifugation              | -                                 | Caspase-3, TNF-α, IL-1β, IL-6, TLR4, NF-κB ↓ | Decreased apoptosis and inflammation                                                                      |                                                                                           | [131]     |
| **Induced pulmonary fibrosis (IPF)**  | Human BM-MSCs Exosomes | Ultracentrifugation              | -                                 | CCL2, ARG1 ↓                          | Reduce bleomycin-induced IPF in mice Reduced collagen deposition and apoptosis                              |                                                                                           | [132]     |
| **Hepatic IR injury**                 | Human iMSCs Exosomes   | Ultrafiltration                   | -                                 | TNF-α, IL-6, HMGB1, caspase-3, Bax ↓ GSH, GSH-Px, SOD ↑ | Suppressed hepatocyte necrosis and sinusoidal congestion Reduced the AST and ALT                           |                                                                                           | [133]     |
| **Liver fibrosis**                    | Human UC-MSCs Exosomes | Ultrafiltration                   | -                                 | AST ↑ Collagen III, TGF-β1, p-Smad2 ↓ | Alleviated hepatic inflammation and collagen deposition in the CCl4-induced fibrotic liver of mice       |                                                                                           | [134]     |
| **Acute liver failure**               | Mouse ASCs Exosomes    | Total Exosome Isolation Kit (Invitrogen) | miR-17 | TNF-α, IFN-γ, IL-1β, IL-6, IL-18, TNXIP, NLRP3, ASC, caspase-1 ↓ | Ameliorated acute liver failure by reducing ALT and AST in mice Reduced activation of TXNIP/NLRP3 inflammasome in macrophages |                                                                                           | [135]     |
| **Intestinal bowel disease (IBD)**    | Human UC-MSCs Exosomes | Ultracentrifugation              | -                                 | TNF-α, IFN-γ, IL-1β, IL-6, IL-17 ↓ TGF-β1, IL-10 ↑ | Ameliorated DSS-induced IBD in mice                                                                       |                                                                                           | [136]     |
| **Neonatal encephalopathy (NEC)**     | Mouse BM-MSCs EVs      | PureExo (101Bio)                 | -                                 | -                                     | Reduced incidence and severity of NEC in premature newborn rats                                           |                                                                                           | [137]     |
| **Abdominal aortic aneurysm**         | Human UC-MSCs EVs      | Ultracentrifugation              | -                                 | IL-6, IL-17, IFN-γ, IL-23, RANTES, KC, MCP-1, MIP-1α, HMGB1 ↓ | Reduced inflammation and macrophage activation in a mouse abdominal aortic aneurysm model                  |                                                                                           | [138]     |
| Category                        | Exosome Source          | Nomenclature | Exosome Isolation       | Related Exosomal Cargo                      | Secreted Factors or Expressed Genes Affected | Immunomodulatory Effects                                                                 | Reference |
|--------------------------------|-------------------------|--------------|-------------------------|---------------------------------------------|---------------------------------------------|------------------------------------------------------------------------------------------|-----------|
| Perinatal brain injury         | Human Wharton’s jelly   | Exosomes     | Ultracentrifugation     | -                                           | TNF-α, IL-6, IL-1β, CXCL10, IL-8, p-ERK1/2, p-JNK, p-p38 | Reduced neuroinflammation in rats with perinatal brain injury [139]                      |           |
|                                | (WJ)-MSCs               |              |                         |                                             |                                             |                                           |           |
|                                | Human WJ-MSCs           | Exosomes     | Ultracentrifugation     | -                                           | Mbp, Map 2 †                               | Reduced neuron-specific cell death in rats with perinatal brain injury [140]            |           |
| Traumatic brain injury (TBI)   | Rat BM-MSCs             | Exosomes     | ExoQuick (System Biosciences) | -                                           | GFAP †                                     | Improved spatial learning in rats with TBI [141]                                       |           |
|                                | Human ASCs              | Exosomes     | ExoQuick (System Biosciences) | MALAT1                                      | TNF-α, IL-1β, IFN-γ †                      | Improved motor behavior in rats with TBI [142]                                         |           |
| Hypoxic-ischemic brain injury  | Human BM-MSCs           | EVs          | PEG6000 precipitation   | -                                           | -                                          | Improved function of brain by reducing the total number and duration of seizures in sheep [143] |           |
| Urethral stricture             | Human UC-MSCs           | Exosomes     | Ultracentrifugation     | miR-146a                                    | α-SMA, collagen I/III, IL-6, IL-1β, IRAK1, TRAF6, NF-xB † | Reduced urethral fibrosis and stricture in rats [144]                                   |           |
| Status epilepticus (SE)        | Human BM-MSCs           | Exosomes     | Anion exchange          | -                                           | TNF-α, IL-1β, MCP-1, SCF, MIP-1a, GM-CSF † IL-10, PDGF-B, IL-6, IL-2 † | Reduced pilocarpine-induced SE in mice Reduced loss of glutaminergic and GABAergic neurons Reduced inflammation in hippocampus [145] |           |
|                                | Human UC-MSCs           | Exosomes     | Ultracentrifugation     | -                                           | GFAP †                                     | Ameliorated SE-induced learning and memory impairment in mice [146]                      |           |
| Retinal IR injury              | Human BM-MSCs           | EVs          | ExoQuick (System Biosciences) | -                                           | TNF-α, IL-6, caspase-3 †                   | Reduced neuro-inflammation and apoptosis [147]                                         |           |
| Laser-induced retinal injury   | Mouse ASCs              | Human UC-MSCs| Exosomes     | Ultracentrifugation       | MCP-1 †                                    | Reduced damage, inhibited apoptosis, and suppressed inflammatory responses in mice [148] |           |
| Sepsis                         | Mouse BM-MSCs           | Exosomes     | Ultracentrifugation     | miR-223                                     | TNF-α, IL-1β, IL-6 †                      | Protected cardiomyocytes fromecal ligation and puncture-induced sepsis in mice through downregulation of SEMA3A and STAT3 [149] |           |
| Graft versus Host Disease (GvHD) | Human UC-MSCs           | EVs          | Ultracentrifugation     | -                                           | IL-2, TNF-α, IFN-γ † IL-10 †              | Prevented acute GvHD in a mouse model of allogeneic hematopoietic stem cell transplantation [150] |           |
|                                | Human BM-MSCs           | Exosomes     | PEG6000 precipitation   | -                                           | TNF-α, IL-1β, IFN-γ †                      | Modulated the patient’s immune cells [151]                                              |           |

Abbreviations: AD, atopic dermatitis; ALI, acute lung injury; BPD, bronchopulmonary dysplasia; DMD, Duchenne muscular dystrophy; ES, embryonic stem cell; IBD, intestinal bowel disease; IPF, induced pulmonary fibrosis; IR, ischemia reperfusion; IVDD, intervertebral disc degeneration; JM, jaw bone marrow; MenSCs, menstrual blood derived MSCs; SE, status epilepticus; UC, umbilical cord; WJ, Wharton’s jelly.
4.1. Macrophage Polarization

There is accumulating evidence that MSC-exosomes promote macrophage polarization from M1 toward M2. M1 macrophages are characterized by the expression of a broad spectrum of pro-inflammatory cytokines and chemokines, such as IL-1β, IL-12, and TNF-α. By contrast, the M2 macrophage phenotype is induced by Th2 cytokines and leads to secretion of anti-inflammatory factors, such as IL-10 and TGF-β, and M2 markers such as IL-1RA, CD163, and C-C motif chemokine 22 (CCL22) [152]. It has been reported that human BM-MSC-exosomes and jaw bone marrow MSC (JM-MSC)-exosomes promote cutaneous wound healing [86], and ameliorate bronchopulmonary dysplasia (BPD) [86] through macrophage M2 polarization. The miR-223 contained in exosomes alleviated inflammation and accelerated wound healing by inducing macrophage M2 polarization. Co-culture with BM-MSC-exosomes increased the expression of miR-223 and decreased the expression of PBX/knotted homeobox 1 (PKNOX1) protein, an important regulator of macrophage polarization, in macrophages isolated from peripheral blood mononucleated cells (PBMCs). Besides, after co-culture with BM-MSC-exosomes CD206-positive macrophages were elevated, and miR-223 inhibitors reversed this elevation [85]. In a high-fat diet (HFD) mouse model, miR-223 deficiency enhanced infiltration of M1 macrophage, and increased production of pro-inflammatory cytokines, but decreased M2-associated biomarkers including peroxisome proliferator-activated receptor γ (PPARγ) and arginase 1 (ARG1) [153]. Another study elucidated that human UC-MSC-exosomes also promote M2 macrophage activation and regulate diabetic cutaneous wound healing [87]. Compared to those from unconditioned UC-MSCs, exosomes from LPS-preconditioned UC-MSCs contained a high level of let-7b, ameliorated inflammation, and promoted wound healing more intensely. UC-MSC-exosomes decreased toll-like receptor 4 (TLR4) and phospho (p)-p65 proteins regardless of LPS preconditioning. After treatment of LPS-preconditioned UC-MSC-exosomes, ARG1, an M2 macrophage marker, was increased, and inducible nitric oxide synthase (iNOS), an M1 macrophage marker, was decreased [88]. The let-7b targets TLR4, activation of which leads to activation of nuclear factor κB (NF-κB). Additionally, let-7b downregulates the expression of cyclooxygenase-2 (COX-2) and cyclin D1 proteins [154]. It was revealed that UC-MSC-exosomes suppress inflammation and promote wound healing by inducing secretion of cytokines from M2 macrophages in rats with severe burn-induced skin inflammation through downregulation of TLR4, NF-κB, and p-p65 expression [89]. A higher level of miR-181c was observed in UC-MSC-exosomes compared to in human dermal fibroblast (HDF)-exosomes. The expression level of miR-181c was decreased by burn injury and was increased after treatment of UC-MSC-exosomes in the cutaneous wound. In addition, treatment of UC-MSC-exosomes reduced the expression of TNF-α and IL-1β and increased the expression of IL-10. These effects were strengthened by exosomes derived from miR-181c-overexpressed UC-MSCs [88]. In an experiment conducted in mouse astrocytes, the expression level of miR-181c was decreased by LPS, a TLR4 receptor ligand. Overexpression of miR-181c increased IL-10 secretion induced by LPS [155]. In primary microglia, oxygen-glucose deprivation (OGD) upregulated TLR4, while miR-181c reversed this upregulation. The miR-181c also downregulated NF-κB and pro-inflammatory cytokines such as TNF-α, IL-1β, and iNOS induced by OGD [156]. In addition, it was found that human MenSC-exosomes induced macrophage M2 polarization, which was confirmed by the increased ARG1/iNOS ratio, which led to the alleviation of inflammation in the diabetic cutaneous wound [89].

Moreover, exosomes derived from various MSCs also play an important role in promoting activation of M2 macrophages in other inflammatory diseases as well as cutaneous wounds. It was found that mouse BM-MSC-exosomes relieve inflammation in atherosclerosis via macrophage M2 polarization in vivo through the let-7/high mobility group AT-Hook 2 (HMGA2)/NF-κB pathway [90]. An enrichment of the let-7 family was found in BM-MSC-exosomes, and treatment of BM-MSC-exosomes upregulated the let-7 level in ApoE–/– mice [90]. Zhao et al. revealed that mouse BM-MSC-exosomes also attenuated myocardial ischemia-reperfusion (IR) injury through polarizing macrophages toward M2 phenotypes (iNOS-CD206+), and increasing IL-10 and ARG1, which are regulated by miR-182 targeting TLR4 [91]. Human BM-MSC-exosomes have been reported to reduce dextran sodium sulfate...
(DSS)-induced IBD in mice through the polarization of M2b macrophages in a metallothionein-2 (MT2A)-dependent manner [92]. Another report revealed that mouse ESC-exosomes improved cardiomyopathy by increasing M2 macrophages and IL-10 release [157]. Additionally, it was reported that rat ASC-exosomes ameliorated myocardial infarction by promoting M2 macrophage polarization, which is regulated by increasing sphingosine-1-phosphate receptor 1 (SIP1) [93]. The importance of the sphingosine 1-phosphate (SIP)/sphingosine kinase 1 (SphK1)/SIPR axis was further confirmed by silencing of SIP1, which abolished the decrease of hypoxia-induced apoptosis by ASC-exosomes in H9c2 cells. Similarly, human ASC-exosomes induced M2 macrophage markers in human PBMCs [94]. Heo et al. revealed that human ASC-exosomes also induce M2 macrophage phenotype by confirming the increased level of transcription factors (e.g., signal transducer and activator of transcription 6 (STAT6), MAF BZIP transcription factor B (MafB), etc.), which led to regulating immunomodulatory and anti-inflammatory effects such as increased Tregs and anti-inflammatory cytokines (e.g., IL-10 and TNF-α-stimulated gene-6 (TSG-6)) [94]. Mouse ASC-exosomes also induced M2 macrophage polarization and reduced inflammation of white adipose tissues (WAT) in obese mice [96]. These effects are dependent on a transcription factor, STAT3, in ASC-exosomes. Furthermore, ASC-exosome-educated M2 macrophages induced proliferation of ASCs themselves and production of lactate from ASCs, which further promoted WAT beiging [95]. However, further studies are needed to understand the detailed underlying molecular mechanism for the regulation of M2 macrophage polarization by MSC-exosomes.

4.2. T Cell Regulation

MSC-exosomes also modulate functions or activities of T cells (Table 3). BM-MSC-exosomes were reported to convert Th1 to Th2, and reduce Th17 differentiation in PBMCs [97]. More importantly, BM-MSC-exosomes increased the level of Tregs in PBMCs. These effects might be mediated by suppression of pro-inflammatory cytokines such as TNF-α and IL-1β, and an increase of anti-inflammatory cytokine TGF-β [9]. Another report also revealed that BM-MSC-exosomes modulate immune reactions in PBMCs from asthmatic patients [98]. The proliferation and immune-suppression capacity of Tregs was promoted by BM-MSC-exosomes through upregulation of IL-10 and TGF-β1 in PBMCs. Tregs was also induced by exosomes derived from TGF-β/IFN-γ-stimulated UC-MSCs [99]. The proposed mechanism of this Treg regulation is an antigen presenting cell (APC)- but not CD4+ T cell-dependent pathway [97]. A previous report demonstrated that differentiation of Tregs is mediated by activated APCs, which is induced by ESC-MSC-exosomes in a myeloid differentiation primary response 88 (MYD88)-dependent manner [100]. It has been also reported that mouse ASC-exosomes induce the increase of Tregs population in the splenic mononuclear cells from mice with streptozotocin-induced autoimmune type 1 diabetes mellitus [100]. Upregulation of Tregs has been also reported in a multiple sclerosis (MS) mouse experimental autoimmune encephalomyelitis model by human BM-MSC-exosomes [101], and a concanavalin A (Con A)-induced mouse liver injury model by mouse BM-MSC-exosomes [102]. Downregulation of proliferation of activated T and B lymphocytes by BM-MSC-exosomes has been also reported [103]. Of note, studies by Del Fattore et al. and Di Trapani et al. have shown that EVs from BM-MSC suppress T cell proliferation indirectly by induction of Treg differentiation, unlike MSCs, which directly suppress T cell proliferation [103,104]. In addition, UC-MSC-EVs purified by size exclusion chromatography only showed an inhibitory effect on T cell proliferation and did not induce cytokine response and monocyte polarization [105]. Further studies are needed to elucidate the molecular mechanism of these regulations by MSC-exosomes.

4.3. Inflammation in Skin

It was reported that human BM-MSC-exosomes reduce photoaging and inflammation in mice, which might be helpful to prevent and treat cutaneous aging [107]. Human ASC-exosomes were reported to enhance neovascularization and the survival of the skin flap in a rat IR injury of the flap transplantation model by reducing inflammation and apoptosis [108]. In this experimental setting, ASC-exosomes derived from H2O2-preconditioned ASCs had better outcomes compared
to those from unconditioned ASCs. Regulation of inflammation is also important to treat atopic dermatitis (AD), a representative skin inflammatory disease. It has been demonstrated that human ASC-exosomes can ameliorate AD in two distinct mouse models via reducing pathological symptoms and expression of multiple cytokines such as IL-4, IL-5, IL-13, IL-17, IL-23, IL-31, TNF-α, IFN-γ, and thymic stromal lymphopoietin (TSLP) [20,109]. Th2 cytokines, such as IL-4, IL-5, IL-13, and IL-31, mainly produced by activated Th2 cells, are crucial contributing factors in the development of allergic inflammation in the skin [158,159]. Notably, Th2 cytokines including IL-4, IL-13, and IL-31 are therapeutic targets for AD [160]. Additionally, ASC-exosomes also reduced the infiltration of inflammatory dendritic epidermal cells (IDECs, CD86+, and CD206+), which led to release of pro-inflammatory cytokines in lesional skin of AD [20]. Taken together, MSC-exosomes are key players in skin regeneration by promoting macrophage M2 polarization with anti-inflammatory properties and reducing pro-inflammatory cytokine-releasing cells such as M1 macrophages and IDECs.

4.4. Immunomodulation in Other Inflammatory Diseases

Immunomodulation by MSC-exosomes was also reported in various inflammatory disease models. Examples are as follows: (1) Exosomes from melatonin-preconditioned rat BM-MSCs reduced the kidney injury in a rat renal IR injury model by decreasing oxidative stress and apoptosis, increasing anti-oxidant and anti-apoptotic proteins, and enhancing angiogenesis [110]. In addition, mouse BM-MSC-exosomes reduced the renal IR injury in a CCR2-dependent manner [111]. Human UC-MSC-exosomes have been also reported to reduce cisplatin-induced acute kidney injury (AKI) in rats in an autophagy-dependent manner [112]; (2) Human UC-MSC-exosomes reduced the experimental autoimmune uveitis in rats [113]; (3) Human placenta-derived MSC (PL-MSC)-exosomes reduced the tissue fibrosis and inflammation in a mouse Duchenne muscular dystrophy (DMD) model partly through the delivery of miR-29c [114]; (4) Human UC-MSC-exosomes improved the pathology of lung, cardiac, and brain in neonatal mice with BPD by reducing the pulmonary inflammation and alveolar-capillary leak potential through the delivery of TSG-6 [115] or macrophage M2 polarization [86]; (5) Targeted delivery of mouse BM-MSC-exosomes by rabies viral glycoprotein (RVG) peptide improved the cognitive function of transgenic APP/PS1 mice by reducing plaque deposition, the level of Aβ, activation of astrocytes, and the expression of pro-inflammatory cytokines TNF-α, IL-β, and IL-6, while increasing the levels of IL-10, IL-4, and IL-13 [116]; (6) Human BM-MSC-EVs improved the neurological impairment and long-term neuroprotection in stoke mice by attenuating the post-ischemic immunosuppression and lymphopenia, and as well as stimulating neurogenesis and angiogenesis [117]; and (7) Mouse BM-MSC-exosomes decreased the threshold for thermal and mechanical stimuli in a mouse diabetic peripheral neuropathy model by regulating multiple factors involved in macrophage polarization through the delivery of miRNAs targeting the TLR4/NF-κB signaling pathway [118].

Other inflammatory diseases, which can be modulated by MSC-exosomes or MSC-EVs, include OA [119,120], intervertebral disc degeneration (IVDD) [123], spinal cord injury [124–126], myocardial infarction [127,128], acute lung injury (ALI) [129–131], idiopathic pulmonary fibrosis (IPF) [132], hepatic IR injury [133], liver fibrosis [134], acute liver failure [135], IBD [92,136], necrotizing enterocolitis [137], abdominal aortic aneurysm [139], brain injuries [139–143], urethral stricture [144], status epilepticus (SE) [145,146], retinal injuries [147,148], sepsis [150], and graft-versus-host disease (GvHD) [150]. The immunomodulation of MSC-exosomes was highlighted in their first clinical application in an allogeneic setting to a patient suffering from steroid refractory GvHD [151]. In this study, MSC-exosomes modulated the status of the patient’s immune cells. The differentiation of Tregs by MSC-exosome-mediated APC activation might contribute to suppression of GvHD [99].

In summary, MSC-exosomes or MSC-EVs suppress inflammatory responses in diverse disease settings by inducing polarization and differentiation of M2 macrophages and Tregs. Although exact cargo compositions and MoA of exosomes need to be further studied, mounting evidence suggests that MSC-exosomes have similar anti-inflammatory and immunomodulatory properties of MSCs, which could be beneficial for the treatment of inflammatory and autoimmune diseases, as well as for skin
regeneration. However, MSC-exosomes may also possess distinct immunomodulatory mechanisms from those of MSCs, which needs to be further elucidated to facilitate application in clinical settings.

5. Anti-Aging Effects of MSC-Exosomes

Aging, defined as irreversible deterioration of physiological processes of organisms over time, is characterized by nine hallmarks: cellular senescence, mitochondrial dysfunction, deregulated nutrient sensing, epigenetic alterations, telomere attrition, genomic instability, altered intercellular communication, and stem cell exhaustion [161,162]. Among these, cellular senescence has recently been focused on as one of the key factors in the complex aging process as it is interlinked with other hallmarks [163]. Senescent cells are accumulated in tissues of vertebrates with age. Interestingly, removal of senescent cells in animals results in the delayed onset of age-associated diseases [164–168]. Senescence is characterized by a stable cell-cycle arrest in the G1 phase and an inflammatory response called senescence-associated secretory phenotype (SASP), which modifies the microenvironment around senescent cells [161]. Senescence is induced by intracellular and extracellular stresses, including replicative stress, DNA damage, oncogene activation, telomere damage or shortening, inflammation, mitochondrial dysfunction, oxidative stress, and drug insults, to eliminate damaged cells, and prevents potential malignant cell transformation [161,169]. Components of the SASP include growth factors, pro-inflammatory cytokines, chemokines, and extracellular matrix remodeling enzymes [170–172]. SASP contributes to inflammaging, a term coined by Franceschi et al. in 2000, which describes low-grade, controlled, asymptomatic, chronic, and systemic inflammation associated with aging processes [173]. Indeed, many evidences point out that inflammaging may ultimately lead to age-related diseases [174–176]. Thus, interventions that suppress SASP and inflammaging processes may hold potential to alleviate various chronic diseases [177]. In addition, senescent cells display the expression of senescence-associated β-galactosidase (SA-β-gal), increases of mRNAs/proteins including p53, p21, p16, and γ-H2AX, and a decrease in cell proliferation [161].

5.1. EVs in Senescence

EVs or exosomes have a role in both transferring the senescence phenotype and alleviating or even rejuvenating senescence cells, depending on their originating cells. Studies suggest that EVs or exosomes act as new components of the SASP and age-related disease markers [169–171]. Age-related changes of EVs or exosomes have been reported to result in the following: (1) an increase in the number of EVs or exosomes released during senescence of fibroblast, epithelial cells, and cancer cells [178,179]; (2) a decrease in the levels of circulating EVs with age, at least from the 30s to 60s in humans, as well as in mice and rats [180–182]; and (3) changes of EV or exosome composition (miRNAs, proteins, or lipids) associated with aging or senescence [171,183–189]. In fact, EVs or exosomes mediate paracrine senescence, transmitting senescence from senescent or diseased cells to normal cells, in both normal and disease conditions [169,190–195]. This paracrine senescence is positively correlated with the uptake of exosomes by target cells and is prevented by inhibition of exosome generation [169].

It has also been reported that various long noncoding RNAs (lncRNAs) are enriched in exosomes from senescent cells and accumulating evidence shows that these RNAs may contribute to the progression of age-related diseases such as atherosclerosis, type 2 diabetes, osteoporosis, OA, rheumatoid arthritis, Parkinson’s disease, and multiple sclerosis [196]. It has also been reported that various long noncoding RNAs (lncRNAs) are enriched in exosomes from senescent cells, and accumulating evidence shows that these RNAs may contribute to the progression of age-related diseases such as atherosclerosis, type 2 diabetes, osteoporosis, OA, rheumatoid arthritis, Parkinson’s disease, and multiple sclerosis. For instance, in atherosclerosis, monocytes exposed to oxidized low-density lipoprotein (oxLDL) drives progression of the disease. A study by Chen et al. has shown that THP-1, a monocyte cell line, treated with oxLDL shows significant upregulation of exosomal lncRNA GAS5, and these exosomes cause apoptosis of endothelial cells [197]. The role of exosomal lncRNA was also highlighted by Ruan et al. In this study, it was found that exosomal lncRNA-p3134
contents in diabetic patients were higher than those in non-diabetic subjects [198]. Senescent cells also exert effects by transferring protein cargo. For instance, exosomes from drug-induced senescent multiple myeloma cells promote activation and proliferation of NK cells by transferring IL-15RA and IL-15 [199]. Taken together, EVs from senescent cells may serve as disease markers.

5.2. Anti-Aging Effects

It has been elusive that circulating mediators are responsible for rejuvenating multiple tissues of old organisms by parabiosis of young organisms [200]. Very recently, it was demonstrated that EVs from young mice plasma extend the lifespan of old mice by delaying aging through exosomal nicotinamide phosphoribosyl transferase (eNAMPT) [201]. Another study also reported that exosomes from young mice could transfer miR-126b-5p to tissue of old mice, and reverse the expression of aging-associated molecules such as p16, mTOR, IGF-1R, and telomerase-related genes including Men1, Mre11a, Tep1, Terf2, Tert, and Tnks, in aged mice [202]. Another report revealed that EVs derived from serum of young mice attenuated inflammaging in old mice by partially rejuvenating aged T-cell immunotolerance [203]. Implantation of hypothalamic stem/progenitor cells, which were genetically engineered to survive from aging-related hypothalamic inflammation, was reported to induce retardation of aging and extension of lifespan in mid-aged mice [204].

More importantly, growing evidence suggests that cellular senescence can be alleviated or reversed by EVs or exosomes derived from stem cells (Table 4) [205–214]. Human ASC-exosomes reduced the high glucose-induced premature senescence of endothelial progenitor cells (EPCs) and enhanced wound healing in diabetic rats [205]. In the same study, overexpression of nuclear factor erythroid 2-related factor 2 (NRF2) in human ASC-exosomes further reduced premature senescence of EPCs, and promoted wound healing in diabetic rats by modulating the expression of various proteins [205]. Since high glucose in diabetic patients induces reactive oxygen species (ROS) and inflammation, which promotes senescence and impairs function of EPCs, reduced senescence of EPCs by ASC-exosomes may be beneficial for the treatment of diabetic foot ulcers [205]. It has also been reported that human ASC-exosomes contain lncRNA MALAT1 and recover function of motor behavior with reduction of cortical brain injury in a rat traumatic brain injury model [142]. Regarding this, a study revealed that the MALAT1 expression is reduced in aged mice and that treatment of human UC-MSC-exosomes containing MALAT1 prevents aging in D-galactose (gal)-treated mice and senescence in H2O2-treated H9C2 cardiomyocytes [206]. MALAT1 is one of the candidates for anti-aging effects in stem cell-derived exosomes, since MALAT1-knockdown in UC-MSCs abolished these effects of UM-MSC-exosomes. Similarly, exosomal miR-146a was known to negatively regulate senescence of MSCs by targeting the NF-κB signaling [191]. Recently, miR-146a in AF-MSC-exosomes was reported to reduce LPS-induced inflammation in the human trophoblast cells [215]. The miR-146a is also known to be enriched in human UC-MSC-exosomes by TNF-α-pre-conditioning, and mediate anti-inflammatory effects in a rat urethral stricture model [145]. Antioxidant enzymes peroxiredoxins (PRDXs) were reported as being highly enriched in iPSC-EVs and BM-MSC-EVs [208]. Transferring of PRDXs by these EVs resulted in alleviation of cellular aging phenotypes such as increases of SA-β-gal, p21, p53, IL-1α, IL-6, and γ-H2AX in both replicative and genetically induced senescent MSCs [209]. Interestingly, proteomic analysis revealed that ASC-exosomes also contain PRDXs such as PRDX1, PRDX4, and PRDX6 [109]. Human ASC-exosomes were also reported to reduce IL-1β-induced senescence in osteoblasts from OA patients [209]. In this study, ASC-exosomes reduced not only the levels of SA-β-gal, γ-H2AX, and IL-6 protein, but also the levels of prostaglandin E2, oxidative stress, and mitochondrial membrane potential. It has been reported that miR-214 in exosomes prevents senescence of endothelial cells by repressing the expression of ataxia telangiectasia mutated (ATM) protein by targeting the 3′-untranslated region (UTR) of its mRNA [216]. Interestingly, the next generation sequencing (NGS) analysis revealed that ASC-exosomes also contain miR-214 (Ha et al. unpublished observation).
Table 4. Anti-senescence effects of exosomes derived from stem cells.

| Exosome Source | Nomenclature | Exosome Isolation | Potential MoA | Senescent Cells | In Vitro Effects | In Vivo Effects | Reference |
|----------------|--------------|-------------------|---------------|----------------|-----------------|----------------|-----------|
| Human ASCs     | Exosomes     | ExoQuick          | NFR2          | HG-induced senescent EPCs | Cell viability, Tube formation ↑ | Wound healing in diabetic rat | [205] |
|                |              | (System Biosciences) |              |                 |                 |                |           |
| Human UC-MSCs  | Exosomes     | Total exosome isolation kit | Reducing NF-κB/TNFα signaling by lncRNA MALAT1 | H2O2-treated H9C2 | SA-β-gal ↓ | Improvement cardiac function in D-gal-induced aged mouse | [206] |
| Human UC-MSCs  | Exosomes     | Ultracentrifugation | TGF-β1 downregulation by miR-675 | H2O2-treated H9C2 | SA-β-gal, p21, TGF-β1 ↓ | Perfusion in ischemic hindlimb | [207] |
| Human BM-MSCs  | Exosomes     | Ultracentrifugation | Unknown | Reduction of ROS by PRDXs enriched in exosomes | Cell growth ↑ | ND | [208] |
| Human iPSCs    | EVs          | Size exclusion chromatography | RS MSCs Progerin-induced senescent MSCs | Cell proliferation ↑ | | | |
| Human ASCs     | Exosomes     | Ultracentrifugation | Unknown | IL-1β-treated OA osteoblasts | SA-β-gal, γ-H2AX ↓ | ND | [209] |
| Rat BM-MSCs    | Exosomes     | Ultracentrifugation | Activation of Wnt/β-catenin signaling | Irradiated rat BM-MSCs | Oxidative stress ↓ | Attenuating radiation-induced bone loss in rat | [210] |
| Mouse ESCs     | Exosome      | ExoQuick          | TGF-β Receptor 2 inhibition by mouse miR-291a-3p (human miR-371a-3p) | RS HDFs AS HDFs | SA-β-gal ↓ | ND | [211] |
| Human ESCs     | Exosome      | Ultracentrifugation | KEAP1 downregulation by miR-200a | D-gal-induced HUVECs | SA-β-gal, p16, p21 ↓ | Pressure ulcer healing in D-gal-induced aged mouse | [212] |
| Human iPSCs    | Exosomes     | Ultracentrifugation | Unknown | RS HDFs Photaged HDFs | SA-β-gal, MMP-3/13 ↓ | ND | [213] |
| Human iPSCs    | Exosomes     | Ultracentrifugation | Unknown | HG-injured HUVECs | SA-β-gal ↓Cell viability, Tube formation↑ | ND | [214] |

Abbreviations: AS, adriamycin-induced cellular senescence; HG, high glucose; ND, not determined; IRS, ionizing radiation-induced senescence; RS, replicative senescence.
Mouse miR-291a-3p was identified to target TGF-β2 receptor and as a cargo of mouse ESC-exosomes [211]. Treatment of mouse ESC-exosomes reduced the SA-β-gal expression and promoted cell proliferation and migration of replicative or adriamycin-induced senescent HDFs [211]. It was reported that human ESC-exosomes inhibited D-gal-induced senescence of human vascular endothelial cells (HUVECs) [212]. Treatment of ESC-exosomes resulted in a decrease in SA-β-gal activity, p16 and p21 protein levels, and ROS in HUVECs, and an increase in cell proliferation, migration, and tube formation of HUVECs. The miR-200a in ESC-exosomes reduced the level of Kelch-like ECH-associated protein 1 (KEAP1) by targeting the 3′-UTR of KEAP1 mRNA. As a result, the level of NRF2, a master regulator of anti-oxidative responses [217], was increased to induce the expression of its downstream targets such as heme oxygenase 1 (HO1), superoxide dismutase (SOD), and catalase (CAT) [213]. ESC-exosomes promoted pressure ulcer healing in D-gal-induced aged mice by reducing endothelial senescence and increasing angiogenesis [212]. Human iPSC-exosomes were reported to protect HDFs from UVB damage, reduce the senescence-associated MMP-1/3 expression, and induce synthesis of collagen type I in both UVB-damaged and senescent HDFs [214]. Human iPSC-exosomes were also reported to reduce SA-β-gal and increase cell viability and tube formation of high glucose-injured HUVECs with unknown mechanism [214]. Exosomes from various cells are also useful as a delivery vehicle of biomolecules to suppress senescence. The miR-675 was discovered as a candidate marker for aging [207]. Delivery of miR-675 through UC-MSC-exosomes reduced the SA-β-gal expression, and the levels of p21 and TGF-β1 proteins in H2O2-induced senescent H9C2 cells by targeted downregulation of TGF-β1. Additionally, miR-675-UC-MCS-exosomes promoted perfusion in ischemic hindlimb by inhibiting the expression of both miRNAs and proteins of p21 and TGF-β1 [207]. Another study reported that exosomes derived from Wnt4-overexpressed mouse thymic epithelial cells (TECs) inhibited dexamethasone-induced aging phenotypes in TECs [218].

Taken together, MSC-exosomes confer anti-senescence effects through their unique miRNA, lncRNA, and enzyme contents. By inducing proliferation and reducing SASP in senescent cells, they hold great potential to reduce senescent cells in tissues. Since removal of senescent cells from tissues was reported to create a pro-regenerative environment [168] and tissue homeostasis [166], application of MSC-exosomes to remove the senescent cells may be a preferable approach to induce the regeneration or rejuvenation of tissues.

6. Cutaneous Wound Healing by MSC-Exosomes

A wound is a type of injury in skin. An open wound is caused by a tear, cut, or puncture, and a closed wound is caused by blunt trauma [219]. Cutaneous wounds can be classified into acute and chronic wounds [220]. Acute wounds are highly prevalent from a loss of dermis and epidermis caused by mechanical, chemical, biological, or thermal injuries. Chronic wounds, on the other hand, are common comorbidities of complex diseases such as obesity, diabetes, and vascular disorders. Four categories of chronic wounds include pressure ulcers, diabetic ulcers, venous ulcers, and arterial insufficiency ulcers according to the Wound Healing Society [221]. Since chronic wounds do not heal within three months, they are considered as non-healing wounds [222,223]. Another major medical issue is pathological wound healing and scar formation, which cause both physiological and psychological challenges [224]. The annual Medicare cost for the treatment of acute and chronic wounds was estimated at from $28.1 to $96.8 billion [225]. In addition, the annual product market for wound care is estimated to reach $15 to $22 billion by 2024 [225].

Cutaneous wound healing is the complex process of restoring the injured skin. It consists of four phases: the homeostasis, inflammatory, proliferative, and remodeling phases [226–228]. Responses in these phases are tightly coordinated to secure vital skin barrier functions [224]. However, the mechanism of cutaneous wound healing and the interplays between a variety of cells during the wound healing process have been only partly delineated [229]. Many cell types interact with each other in a highly sophisticated sequence during the cutaneous wound healing process as follows [230]: (1) the platelets initiate the formation of the blood clots, which consist of platelets, red blood cells,
and extracellular matrix molecules in the first homeostasis phase; (2) neutrophils, monocytes, as well as macrophages are major players during the inflammatory phase. Chemotactic factors released by neutrophils attract monocytes and cytokines from macrophages and stimulate migration of fibroblasts to enter the injured site from the surrounding normal tissues; (3) angiogenesis and vascularization of endothelial cells provide oxygen supply to support proliferation of migrated cells in the wound site during the proliferative phase. Fibroblasts also differentiate into myofibroblasts to generate a tensile strength in the wound. In addition, fibroblasts secrete growth factors, which activate migration and proliferation of keratinocytes. Reepithelialization is completed by stopping migration of cells by contact inhibition [230]; and (4) remodeling through apoptosis of fibroblasts, myofibroblasts, and other cells, and degradation of extracellular matrix occur during the wound scar remodeling phase, which spans months to years. Adverse scarring, caused by aberrant wound healing, includes chronic non-healing wounds and pathological scarring such as hypertrophic scars and keloids, and it affects millions of people globally since currently no effective treatment option is available [224]. The prevention or reduction of scars is also an important issue to solve in the regenerative aesthetics [231].

MSC-EVs or MSC-exosomes orchestrate all phases of skin wound healing because of their ability to modulate inflammation, activate migration and proliferation of various cells including immune cells, fibroblasts, and keratinocytes, and even ameliorate scarring (Table 5) [85,87,88,205,226,231–245]. As an example, complete reepithelialization was reported in a rabbit cutaneous wound healing model by EVs from rabbit ASCs and BM-MSCs with an unknown mechanism [232]. Human ASC-EVs were also reported to enhance cutaneous wound healing in rat [233].

### Table 5. Wound healing effects of MSC-exosomes.

| Exosome Source | Nomenclature | Exosome Isolation | Related Exosomal Cargo | Factors Affected | Animal for In Vivo Study | Reference |
|----------------|--------------|-------------------|------------------------|------------------|--------------------------|-----------|
| Human JM-MSCs Exosomes | Ultracentrifugation ExoQuick (System Biosciences) | miR-223 | TNF-α ↓, IL-10 ↑ | Mouse | [85] |
| Human BM-MSCs Exosomes | | | | | |
| Human UC-MSCs Exosomes | Ultracentrifugation | let-7b | TLR4, p-p65, iNOS ↓, p-STAT3, p-AKT, ARG1 ↑ | Rat | [87] |
| Human UC-MSCs Exosomes | PureExo (101Bio) | miR-181c | TNF-α, IL-1β, TLR4, p65, p-p65 ↓, IL-10 ↑ | Rat | [88] |
| Human ASCs Exosomes | ExoQuick (System Biosciences) | - | NOX1, NOX4, IL-6, IL-1β, TNF-α ↓, SMP30, p-VEGFR2 ↑ | Rat | [205] |
| Rabbit ASCs EVs | Ultracentrifugation | - | - | Rabbit | [232] |
| Human ASCs EVs | Ultracentrifugation | - | - | Rat | [233] |
| Human ASCs Exosomes | ExoQuick (System Biosciences) | - | N-cadherin, cyclin 1, PCNA, collagen I/III, elastin ↑ | Mouse | [234] |
| Human ASCs Exosomes | ExoQuick (System Biosciences) | - | Collagen I/III, TGF-β1/3, MMP1/β, α-SMA ↓ | Mouse | [235] |
| Human fetal dermal MSCs Exosomes | ExoQuick (System Biosciences) Jagged 1 | Collagen I/III, elastin, fibronectin mRNA ↑ | Mouse | [236] |
| Human UC-MSCs Exosomes | Ultracentrifugation Wnt4 | CK19, PCNA, collagen I ↑ | Rat | [237] |
| Human UC blood-MSCs Exosomes | | | Ang, Ang1, HFG, VEGF ↑ | Rat | [238] |
| Human UC-MSCs Exosomes | Ultracentrifugation Wnt4 | β-catenin, N-cadherin, PCNA, Cyclin D3 ↑ | Rat | [239] |
| Human iPSC-MSCs Exosomes | Ultracentrifugation | - | Collagen I/III, elastin, ↑ | Rat | [240] |
| Human UC-MSCs Exosomes | Ultracentrifugation | - | α-SMA, collagen I ↓ | Mouse | [241] |
| Human gingival MSCs Exosomes | Size exclusion chromatography | - | Collagen ↑ | Rat | [242] |
| Dog BM-MSCs Exosomes | Ultracentrifugation | - | α-SMA ↓ | Dog | [243] |
6.1. Homeostasis Phase

During the homeostasis phase, the formation of blood clots by platelets protects the injured site. Up to now, no direct evidence has been available that shows the involvement of MSC-exosomes in blood clotting during wound healing. A recent result might suggest the potential benefit of MSC-exosomes on blood clotting in the wound healing process; human UC-MSC-EVs have been reported to induce blood coagulation in vitro [244]. However, further studies are required to analyze the effects of MSC-EVs or MSC-exosomes in blood clotting in both healthy and disease conditions.

6.2. Inflammatory Phase

Regulation of inflammation is also important in skin regeneration during the wound healing process. Although inflammation is one phase of the normal skin repair cascade, the prolonged inflammation is harmful and may cause excessive scarring [245]. The prolonged inflammation happens mainly in chronic or burn wounds [226,246] and it is of importance to appropriately transit from inflammatory to proliferative phases in normal wound healing [247]. Macrophages are crucial in the wound healing process, which should appropriately transition from M1 to M2 macrophages [248,249]. M2 macrophages have anti-inflammatory properties, which are promoted in order to repair wounds in the latter phases of skin wound healing [248,249]. As mentioned earlier, MSC-exosomes promote the polarization of macrophages from M1 to M2 in cutaneous wound healing models (see 4. Anti-inflammation and immunomodulation by MSC-exosomes): (1) human BM-MSC-exosomes and JM-MSC-exosomes promote cutaneous wound healing in mice by transferring miR-223 [85]; (2) human UC-MSC-exosomes promoted diabetic cutaneous wound healing in rats by delivering let-7b [88]; and (3) human UC-MSC-exosomes enhanced the wound healing in rats with severe burn injury through miR-181c transfer [88].

6.3. Proliferative Phase

During the proliferative phase, fibroblasts from surrounding normal tissues migrate into the injured site. These fibroblasts produce various matrix proteins including collagen I and III to strengthen the newly formed scar tissue. MSC-exosomes affect these dermal fibroblasts to promote migration and proliferation, and produce collagen, elastin, and fibronectin: (1) human ASC-EVs or ASC-exosomes induced migration and proliferation of dermal fibroblasts or keratinocyte in vitro [234,235]; (2) human ASC-exosomes induced collagen I/III and elastin in HDFs, and they enhanced cutaneous wound healing in mice [234,235]; (3) human fetal dermal (FD)-MSC-exosomes induced the expression of collagen I/III, elastin, and fibronectin mRNAs by activating the Notch pathway through delivering Jagged 1 protein [236]; and (4) human UC-MSC-exosomes were shown to contain Wnt4 and accelerated reepithelialization of burn skin in rats [237]. The wound healing effects were inhibited when the Wnt4 expression in UC-MSC-exosomes was knock-downed by siRNA. Furthermore, human MSC-exosomes were reported to induce proliferation and migration of fibroblasts in vitro from diabetic wound patients [250]. The positive effects of MSC-exosomes on keratinocytes were also reported as follows: (1) human UC-MSC-exosomes protect the immortalized human keratinocytes HaCaT from heat-induced apoptosis by activating the AKT pathway [237]; and (2) human WJ-MSC- and iMSC-exosomes increased the secretion of collagen in HaCaT [251].

As mentioned above, angiogenesis is of importance to support the oxygen needed for the proliferation of fibroblasts or other cells in the injured site [229]. It has been also reported that MSC-exosomes induce angiogenic activity of endothelial cells. Human ASC-exosomes induced tube formation of HUVECs by delivery of miR-125a, which suppresses the expression of angiogenic inhibitor delta-like 4 (DLL4) [252]. Human BM-MSC-EVs or rat BM-MSC-exosomes were also reported to enhance angiogenesis in stroke mice [118] or in rats with renal IR injury [110], respectively. Exosomes from human endometrial MSCs were reported to increase proliferation, migration, and angiogenesis of HUVECs with increased expression levels of angiogenic markers including Tie2, angiopoietin
1 (Ang1), Ang2, and vascular endothelial growth factor (VEGF) [253]. In addition, the following pro-angiogenic effects of MSC-exosomes have been confirmed in vivo: (1) human umbilical cord blood (UCB)-MSC-exosomes with thrombin preconditioning accelerated cutaneous wound healing in rats with full-thickness wounds. Human UCB-MSC-exosomes increased the angiogenic factors such as angiogenin (Ang), Ang1, hepatocyte growth factor (HGF), and VEGF, while reducing TNF-α and IL-6 [238]; (2) human UC-MSC-exosomes enhanced angiogenesis in rats through the Wnt4/β-catenin pathway. The pro-angiogenic effects of human UC-MSC-exosomes was abolished when the Wnt4 expression was knock-downed by shRNA [239]; and (3) human iMSC-exosomes accelerated both the formation and maturation of new vessels in the wound sites with unknown mechanism [241].

6.4. Remodeling Phase

MSC-exosomes might be beneficial to further reduce scar formation. Uncontrolled accumulation of myofibroblasts in the wound sites causes scar formation. Recently, human UC-MSC-exosomes have been reported to reduce scar formation by inhibiting accumulation of myofibroblasts in mice [242]. A variety of proteases such as matrix metalloproteinases (MMPs) are necessary for all phases of the cutaneous wound healing process [254]. During the remodeling phase, controlled release of MMPs by fibroblasts, macrophages, epidermal cells, and endothelial cells contributes to degrading the majority of collagen III fibers [255]. Regulation of extracellular matrix remodeling by ASC-exosomes has been reported [235]. In this study, it was demonstrated that ASC-exosomes promoted scarless cutaneous wound repair by regulating the ratios of collagen I-to-collagen III, TGF-β3-to-TGF-β1, and MMP3-to-MMP1.

6.5. Proteolytic Environment

Uncontrolled protease activities are known to be associated with impaired wound healing [256]. Additionally, prolonged high levels of protease activities have been suggested to be associated with delayed wound healing in chronic wounds [254–257]. In fact, elevated levels and activities of collagenase (MMP-1 and MMP-8) and gelatinases (MMP-2 and MMP-9) are characteristics of chronic wounds [255]. This highly proteolytic environment is not favorable for advanced biologicals such as growth factors [258]. In fact, the use of platelet-derived growth factor (PDGF) for treatment of chronic wounds has been reported with modest effect [259]. Based on this, a clinical study for the treatment of chronic wounds with a combination of topical growth factors and proteinase inhibitors was recently initiated [260]. The proteolytic environment of chronic wounds might be also unfavorable for the treatment of MSC-exosomes, since the surface proteins on the exosomes are susceptible to proteolysis, which may change the interaction between exosomes and recipient cells [261]. Therefore, a protease-resistant formulation of MSC-exosomes would be necessary for the maximum efficacy, especially for topical applications, as reported for PDGF [262,263]. Recently, human gingival MSC (GMSC)-exosomes with chitosan/silk hydrogel showed enhanced wound healing in diabetic rats with appropriate swelling and moisture retention capacity suggested as effects of this hydrogel [242]. This hydrogel may also provide protection of exosomes from proteases in the wound site.

6.6. Animal Models

Most of the animal studies for wound healing with MSC-exosomes have been performed in rodents, except for two studies with rabbit and dog [232,243] (Table 5). However, the structure and physiology of rodent skin do not reflect those of human skin. Pigs are the most optimal preclinical models for wound healing because of the highest similarities between pig and human skin including skin architecture, hair density, and physiology of the wound healing process [264–268]. It is necessary to confirm the effects of MSC-exosomes on cutaneous wound healing in pig models for better understanding of MoA and clinical applications.
6.7. ASC-Exosomes

The beneficial effects of fat graft on wound repair are widely accepted, while the underlying mechanism remains unknown [269]. These effects might be related to exosomes from the subcutaneous fat layer. Recently, it has been revealed that human ASC-exosomes induce proliferation and migration of HDFs, and the expression of N-cadherin, cyclin 1, PCNA, collagen I/III, and elastin in HDFs in vitro, which results in reduced scar formation in mice by regulating extracellular matrix remodeling [234,235]. No direct evidence that shows an advantage of ASC-exosomes over exosomes from other MSCs is available. ASCs, however, are distinct in immunomodulation compared to BM-MSCs. BM-MSCs enter the wound site through the blood supply to initiate the first phase of wound healing [270]. In the injured site, BM-MSCs prolong and enhance the inflammation by increasing survival and function of neutrophils [271]. Under hypoxic conditions, which induces the activation of TRL4, BM-MSCs secreted pro-inflammatory factors and decreased the polarization of macrophage from M1 to M2 phenotype [272,273]. Therefore BM-MSCs in the wound site might not induce the anti-inflammatory M2 macrophages without enough oxygen supply by neovascularization. On the contrary, phenotype and secretome of ASCs were largely unaffected by prolonged hypoxia [274], and the CM from ASCs showed better inducing effects of the anti-inflammatory M2 macrophage phenotype than the CM from BM-MSCs [275]. These results suggest that ASC-exosomes might be more beneficial than BM-MSC-exosomes to induce appropriate wound healing processes. In summary, MSC-EVs or MSC-exosomes contribute to each phase of wound healing by inducing M2 polarization and stimulating dermal fibroblasts to produce structural proteins and proteases necessary for remodeling of the extracellular matrix.

7. MSC-Exosome-Induced Hair Growth

Hair follicle cycling is a dynamic and complex process involving alternating phases of rapid growth (anagen), regression (catagen), and quiescence (telogen) [276]. Hair follicles, which reside in the dermal layer of the skin, are made up of various cell types including dermal papilla (DP) cells and outer root sheath (ORS) keratinocytes, each having distinct roles [277]. In addition to these cells, ASCs located in the adipose tissue below dermis may also affect hair cycling as ASCs differentiate into mature adipocytes and surround hair follicles during the telogen to anagen transition [278]. Although a direct relationship between dermal papilla cells and ASCs has not been elucidated, it can be anticipated that ASCs exert effects on hair growth, as numerous studies have shown that transplantation of ASCs and CM from ASCs enhance proliferation of DP cells in vitro and promote hair growth in mice and human [279–281]. Indeed, interactions between these cell types through various mediators lead to transition from the telogen to anagen phase. Activation of the Wnt/ß-catenin signaling is one of the main pathways involved in the hair follicle development. Previous studies have shown that dermal Wnt ligands regulate hair-inducing activity of DP cells by maintaining the anagen phase [282,283]. In addition, growth factors such as fibroblast growth factor-5 (FGF-5) produced by ORS cells or insulin-like growth factor-1 (IGF-1) produced by DP cells increase proliferation of hair follicle cells [284,285]. Thus, the Wnt/ß-catenin signaling and secretion of growth factors are crucial for hair growth.

Dysregulation of hair cycling caused by various factors such as environmental, genetic, hormonal, and aging, results in hair loss [286–288]. Currently, finasteride and minoxidil are the mainstay treatments for alopecia, although they are not fundamental treatments that induce hair growth, not to mention having various side effects associated with them [289,290]. Hair transplantation is frequently utilized as a fundamental treatment of hair loss but it is an invasive procedure and graft survival rate largely depends on the surgeon [291]. There is a strong unmet need of a minimally invasive treatment that not only retards hair loss but also promotes hair growth.
7.1. The Effects of DP-Exosomes on Hair Cells

As DP cells are the key player in hair follicle cycling as they secrete growth factors, activate the Wnt signaling, and promote differentiation of hair follicle stem cells, it can be anticipated that exosomes derived from DP cells can also modulate hair follicle cycling. Indeed, studies have shown that exosomes derived from DP cells (DP-exosomes) promote hair growth. Cutaneous injection of human DP-exosomes increased the anagen to catagen ratio in mice and stimulated proliferation and β-catenin expression of ORS cells [292]. Exosomes derived from 3D culture of human DP cells increased the percentage of Ki67-positive cells in cultured hair follicles and induced hair follicles in mice implanted with human DP spheres by activating the Wnt and bone morphogenic protein (BMP) signaling [293]. A study by Yan et al. identified 34 differentially expressed miRNAs that are involved in proliferation and differentiation of hair follicle stem cells by goat DP-exosomes [294].

7.2. The Effects of MSC-Exosomes on Hair Growth

Similar to DP-exosomes, MSC-exosomes are also known to carry a myriad of growth factors and Wnt activators in their cargo. For instance, human UC-MSC-exosomes were found to transport Wnt4 and Wnt11 and subsequently activate the Wnt signaling and promote cell proliferation in target cells [237,239,295]. Therefore, MSC-exosomes are attractive treatment options for hair growth as well. However, to date, there is only one publication reporting the effects of MSC-EVs on hair growth [296]. The authors showed that mouse BM-MSC-EVs promoted proliferation of human DP cells and induced secretion of growth factors such as VEGF and IGF-1, which are essential for hair growth [285,297,298]. In addition, when mice were intradermally injected with BM-MSC-EVs, an increased anagen to telogen ratio was evident in C57BL/6 mice, along with elevated Wnt protein levels in the dorsal skin. These results suggest that MSC-EVs or MSC-exosomes might have the potential to promote hair growth. Further studies will be necessary to elucidate the potential of various MSC-exosomes on hair follicle cycling.

8. Repair and Regeneration of Skin barrier by MSC-Exosomes

The skin is the largest organ in the human body, comprising about 15% of the total body weight, and is well known as the barrier between the external environment and the human body, preventing loss of moisture and protecting the body from UV light, pathogens, chemicals, and mechanical injuries [299]. The skin is composed of three layers: epidermis, dermis, and hypodermis. The epidermis is the outermost layer of skin and functions as the waterproof barrier. The dermis is a layer below the epidermis, consisting of tough connective tissues, hair follicles, sebaceous glands, apocrine glands, lymphatic vessels, blood vessels, and sweat glands. The hypodermis (also known as subcutaneous tissue) is the deepest layer of skin and is composed of fat and connective tissue [300,301].

8.1. Skin Barrier

The skin barrier is commonly divided into three distinct functional barriers: microbiome, chemical, and physical barriers [302]. The microbiome barrier comprises the outer side of the skin barrier and is composed of diverse microbial communities such as bacteria, fungi, and viruses [295]. The skin microbiome can protect the body against exogenous exposure and invasion of pathogens and can affect immune cell maturation in the skin development. It also functions as the skin immune mediator, which cross-talks between skin cells and the skin immune system [302]. In some cases, altered microbial states result in skin disease [303]. As an example, the increased abundance of Gemella and Streptococcus species are observed in AD [304].

The chemical barrier provides the acidic surface pH, which is the key factor of desquamation and regeneration of the skin barrier [303]. It also provides the lipid barrier of ceramides, cholesterol, and free fatty acids, consisting of a molar ratio of 1:1:1 [305]. The lipids prevent loss of moisture from skin and invasion of environmental substances. Furthermore, free fatty acids contribute to the
homeostasis of the barrier function, maintaining acidic pH in skin [306]. In addition, the chemical barrier, especially the biochemical barrier, provides antimicrobial peptides. Antimicrobial peptides are a major factor of the innate immune systems and build the first line of defense against bacteria and viruses [307].

The physical barrier consists of stratum corneum (SC) and tight junction (TJ). The SC is the outermost layer of epidermis consisting of dead keratinocytes (corneocytes) [308]. Living keratinocytes are transformed into non-living corneocytes during cornification. Cornification is completed by the replacement of the cell membrane with a layer of ceramides covalently linked to the cornified envelope. This ceramide–corneocyte complex in SC contributes to the skin’s barrier function [309]. The epidermal TJ not only anchors cells to the neighboring cells, but also prevents the escape of moisture between cells [310]. If TJ is damaged, the Langerhans or dendritic cells, which are located below the TJ network, stretch their dendrites to the upper side of TJ, and then are activated by allergens and lead to allergic responses [301,311].

Dysfunction and damage of the skin barrier leads to several diseases such as AD [310], psoriasis [310], rosacea [312], and acne vulgaris [313]. Up to now, most of the therapeutic approaches for these diseases have targeted inflammation: (1) dupilumab, a dual inhibitor of IL-4 and IL-13, was recently approved to treat AD [314]; (2) monoclonal antibodies inhibiting IL-12, IL-23, or IL-17 are being developed for the treatment of psoriasis [315]; (3) a topical drug, ivermectin, for the treatment of mild-to-moderate rosacea has an anti-inflammatory effect [316]; and (4) anti-inflammatory drugs are also used to treat acne vulgaris, although the first line treatment of acne vulgaris is antibiotics [317]. Moisturizers, used to reduce xerosis or dryness, could prove to be toxic to individuals with compromised skin while being harmless to those with normal skin [318]. Physiologic lipid-based barrier creams, containing three essential lipids including ceramides, cholesterol, and free fatty acids, have been reported to improve barrier function and reduce pruritus as well [318]. However, currently no treatment option is available to repair or regenerate skin barrier functions.

8.2. The Effects of ASC-Exosomes on Skin Barrier

Recently, human ASC-exosomes have been reported to promote epidermal barrier repair in a mouse AD model [109]. Repeated exposures of oxazolone to hairless mice induced AD-like symptoms including inflammation and skin barrier abnormalities [319]. Subcutaneous injection of ASC-exosomes induced restoration of the skin barrier by production of ceramides and dihydroceramides with long acyl chains in a dose-dependent manner. ASC-exosomes also induced synthesis of sphingoids including sphingosine and S1P, increased SphK1 activity, and reduced S1P lyase (S1P1) activity in the injured skin. As mentioned previously, the S1P/Sphk1/S1PR axis is of importance for inducing M2 macrophage polarization by ASC-exosomes, which reduce inflammation and promote cutaneous wound healing [94]. Further study will be needed to elucidate the role of M2 macrophage polarization by ASC-exosomes in skin barrier repair. In addition, ASC-exosomes increased the number of epidermal lamellar bodies and formation of the lamellar layer at the interface of SC and stratum granulosum. Transcriptome analysis of diseased skins revealed that ASC-exosomes reversed the abnormal expression of genes involved in skin barrier maintenance, lipid metabolism, the cell cycle, and inflammatory responses induced by repeated oxazolone exposures. These results suggest that ASC-exosomes could be a promising cell-free treatment for the regeneration of the skin barrier in various diseases with skin barrier defects.

9. Application of MSC-Exosomes for Regenerative Aesthetics

Physical changes in skin over time produce psychosocial impacts that significantly affect social interactions [320]. With the global increase of older individuals over 65, there is an expanding demand for repair or rejuvenating products and procedures for aged skin [300,320]. Stem cell conditioned media (CM), mostly from the culture of MSCs, have been used as a skin care product for anti-aging, anti-wrinkle, and skin and hair care [321]. MSC-CM contain beneficial secretomes, including secreted growth factors as well as exosomes. However, MSC-CM also contain
unintended ingredients including media components and additives, and cellular waste such as lactate and ammonia, both of which are restricted in cosmetics [322,323]. On the contrary, isolated MSC-exosomes avoid these potential harmful components. Currently, the tangential flow filtration (TFF) method is recommended as a suitable industrial-scale method to isolate exosomes among various techniques [40,324]. The TFF method can markedly reduce the levels of lactate and ammonia from exosome preparation (Ha et al. unpublished observation). Recently, it has been demonstrated that human ASC-exosomes isolated by the ExoSCRT™ technology, a TFF-based exosome isolation method, are safe, showing no adverse effects in GLP toxicological tests including skin sensitization, in vitro photosensitization, eye and skin irritation, or acute oral toxicity in accordance with OECD guidelines [325]. In addition, the commercial product ASCE™ (the trademark of ExoCoBio), the ASC-exosome isolated by the ExoSCRT™ technology, was firstly registered as a cosmetic ingredient in the International Cosmetic Ingredient Dictionary (ICID). The TFF-isolated ASC-exosomes have multiple effects on the skin: (1) inducing regeneration of epidermal skin barrier by increasing synthesis of ceramides, dihydroceramides, sphingosine, and S1P [110]; (2) reducing inflammation through downregulation of multiple cytokine levels [20,109,325]; (3) reducing the level of TSLP, a pruritus-causing cytokine [110]; (4) inducing synthesis of collagen and elastin in HDFs [325]; and (5) inducing proliferation of HDFs and HDPs (Ha et al. unpublished observation). Recently, a potential effect of ASC-exosomes on subcutaneous fat has been also suggested. Mouse ASC-exosomes promoted WAT beiging through induction of M2 macrophage polarization in WAT of obese mice [95]. Under the same condition, ASC-exosomes induced proliferation of ASCs themselves. Further studies are needed to decipher the effects of human ASC-exosomes on subcutaneous fat in normal physiological conditions.

The safety and efficacy of secretomes from different cells were analyzed for skin and wound care products, and it was found that secretome from ASCs is safer and more effective than that from BM-MSCs in many aspects: (1) lack of expression of major histocompatibility complex (MHC) class II on ASCs; (2) induction of higher levels of anti-inflammatory M2 macrophages by ASC-CM than by BM-MSC-CM; and (3) suppression of cancer growth by ASC-exosomes both in vivo and in vitro [326,327]. ASC-exosomes could be a preferable regenerative aesthetic ingredient since an important function of ASCs in skin is signaling to surrounding cells to induce the differentiation of dermal fibroblasts and keratinocytes, and activate epidermal stem cells including hair follicles [326]. A pioneering cosmeceutical product, the ASCE+™ lyophilized human ASC-exosomes (ASCE+ is the trademark of ExoCoBio), showed various beneficial effects including anti-inflammation and reduction of downtime after ablative skin treatments such as laser therapies (unpublished observation). Taken together, ASC-exosomes could be a next-generation product for the regenerative aesthetics, which affects multiple layers of skin including the epidermis (keratinocytes), dermis (fibroblast, inflammatory cells, and hair follicle), and potentially the hypodermis (subcutaneous fat) (Figure 1).
10. Conclusions

With the recent burst of research, MSC-exosomes are now widely accepted as next-generation cell-free therapeutics for intractable diseases. Many challenges in industrialization of exosomes are still out there such as large-scale culture of MSCs, continuous supply of MSCs with comparable therapeutic effects, and accurate determination of quantity and quality of exosomes. However, technical advances in the MSC cell therapy field, with the expected first marketing approval by the US FDA in the near future [328], are also able to be integrated in the exosome industry soon. The use of immortalized MSCs, with similar functionalities and safety profile compared to naïve MSCs, might be also an alternative strategy for stable production of MSC-exosomes [329,330]. Successful commercialization of MSC-exosomes may provide a completely new therapeutic paradigm for human healthcare.

**Author Contributions:** Conceptualization, D.H.H., J.H.L., Y.W.Y., and B.S.C.; investigation, D.H.H., H.-k.K., J.H.L., and Y.W.Y.; data curation, D.H.H., H.-k.K., and Y.W.Y.; writing—original draft preparation, D.H.H. and Y.W.Y.; writing—review and editing, D.H.H., H.-k.K., J.L., H.H.K., G.-H.P., S.H.Y., J.Y.J., and H.C.; visualization, D.H.H., H.-k.K., S.S., and Y.W.Y.; supervision, Y.W.Y. and B.S.C.; project administration, Y.W.Y.; funding acquisition, B.S.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This review was funded by ExoCoBio Inc.

**Conflicts of Interest:** Y.W.Y. and B.S.C. are founders and stockholders of ExoCoBio Inc. D.H.H., H.-k.K., J.H.L., S.S., Y.W.Y., and B.S.C. are employees of ExoCoBio Inc. Other authors declare no conflict of interest.

**References**

1. Yi, Y.W.; Lee, J.H.; Kim, S.Y.; Pack, C.G.; Ha, D.H.; Park, S.R.; Youn, J.; Cho, B.S. Advances in analysis of biodistribution of exosomes by molecular imaging. *Int. J. Mol. Sci.* 2020, 21, 665. [CrossRef] [PubMed]
2. Chargaff, E.; West, R. The biological significance of the thromboplastic protein of blood. *J. Biol. Chem.* 1946, 166, 189–197. [PubMed]
3. Johnstone, R.M.; Adam, M.; Hammond, J.R.; Orr, L.; Turbide, C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). *J. Biol. Chem.* 1987, 262, 9412–9420.
1. Plieth, J.; Armstrong, M. Exosomes Start to Deliver Deals. Vantage. 28 January 2019. Available online: https://www.evaluate.com/vantage/articles/news/snippets/exosomes-start-deliver-deals (accessed on 13 December 2019).

2. Cross, R. Meet the Exosome, the Rising Star in Delivery. Chemical & Engineering News. 30 July 2018. Available online: https://cen.acs.org/business/start-ups/Meet-exosome-rising-star-drug/96/i131 (accessed on 13 December 2019).

3. Zipkin, M. Exosome redux. Nat. Biotechnol. 2019, 37, 1395–1400. [CrossRef]

4. Hildreth, C. Top 4 Most Richly Funded Exosome Startups. BioInformant. Available online: https://bioinformant.com/top-exosome-companies/ (accessed on 13 December 2019).

5. Phinney, D.G.; Prockop, D.J. Concise review: Mesenchymal stem...
26. Trivedi, P.; Hematti, P. Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells. Exp. Hematol. 2008, 36, 350–359. [CrossRef] [PubMed]

27. Sabapathy, V.; Kumar, S. hiPSC-derived iMSCs, NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine. J. Cell. Mol. Med. 2016, 20, 1571–1588. [CrossRef]

28. Crisan, M.; Yap, S.; Casteilla, L.; Chen, C.-W.; Corselli, M.; Park, T.S.; Andriolo, G.; Sun, B.; Zheng, B.; Zhang, L.; et al. A Perivascular Origin for Mesenchymal Stem Cells in Multiple Human Organs. Cell Stem Cell 2008, 3, 301–313. [CrossRef]

29. Elahi, F.M.; Farwell, D.G.; Nolta, J.A.; Anderson, J.D. Preclinical translation of exosomes derived from mesenchymal stem/stromal cells. Stem Cells 2019. [CrossRef]

30. Katsuda, T.; Tsuchiya, R.; Kosaka, N.; Yoshioka, Y.; Takagaki, K.; Oki, K.; Takeshita, F.; Sakai, Y.; Kuroda, M.; Ochiya, T. Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes. Sci. Rep. 2013, 3, 1197. [CrossRef]

31. Del Fattore, A.; Luciano, R.; Saracino, R.; Battafarano, G.; Rizzo, C.; Pascucci, L.; Alessandri, G.; Pessina, A.; Perrotta, A.; Fierabracci, A.; et al. Differential effects of extracellular vesicles secreted by mesenchymal stem cells from different sources on glioblastoma cells. Expert. Opin. Biol. Ther. 2015, 15, 495–504. [CrossRef]

32. Lopez-Verrilli, M.A.; Caviedes, A.; Cabrera, A.; Sandoval, S.; Wyneken, U.; Khoury, M. Mesenchymal stem cell-derived exosomes from different sources selectively promote neuritic outgrowth. Neuroscience 2016, 21, 129–139. [CrossRef]

33. Zhu, Y.; Wang, Y.; Zhao, B.; Niu, X.; Hu, B.; Li, Q.; Zhang, J.; Ding, J.; Chen, Y.; Wang, Y. Comparison of exosomes secreted by induced pluripotent stem cell-derived mesenchymal stem cells and synovial membrane-derived mesenchymal stem cells for the treatment of osteoarthritis. Stem Cell Res. Ther. 2017, 8, 64. [CrossRef]

34. Villatoro, A.J.; Alcoholado, C.; Martin-Astorga, M.C.; Fernández, V.; Cifuentes, M.; Becerra, J. Comparative analysis and characterization of soluble factors and exosomes from cultured adipose tissue and bone marrow mesenchymal stem cells in canine species. Vet. Immunol. Immunopathol. 2019, 208, 6–15. [CrossRef] [PubMed]

35. Tracy, S.A.; Ahmed, A.; Tigges, J.C.; Ericsson, M.; Pal, A.K.; Zurakowski, D.; Fauza, D.O. A comparison of clinically relevant sources of mesenchymal stem cell-derived exosomes, bone marrow and amniotic fluid. J. Pediatr. Surg. 2019, 54, 86–90. [CrossRef] [PubMed]

36. Vakhshiteh, F.; Atyabi, F.; Ostad, S.N. Mesenchymal stem cell exosomes: A two-edged sword in cancer therapy. Int. J. Nanomed. 2019, 14, 2847–2859. [CrossRef] [PubMed]

37. Takahara, K.; Li, M.; Inamoto, T.; Nakagawa, T.; Ibuki, N.; Yoshikawa, Y.; Tsujino, T.; Uchimoto, T.; Saito, K.; Takai, T.; et al. microRNA-145 mediates the inhibitory effect of adipose tissue-derived stromal cells on prostate cancer. Stem Cells Dev. 2016, 25, 1290–1298. [CrossRef]

38. Willis, G.R.; Mitsialis, S.A.; Kourembanas, S. “Good things come in small packages”: Application of exosome-based therapeutics in neonatal lung injury. Pediat. Res. 2018, 83, 298–307. [CrossRef]

39. Pachler, K.; Ketteri, N.; Desgeorges, A.; Dunai, Z.A.; Laner-Plamberger, S.; Streif, D.; Strunk, D.; Rohde, E.; Gimona, M. An in vitro potency assay for monitoring the immunomodulatory potential of stromal cell-derived extracellular vesicles. Int. J. Mol. Sci. 2017, 18, 1413. [CrossRef]

40. Gimona, M.; Pachler, K.; Laner-Plamberger, S.; Schallmoser, K.; Rohde, E. Manufacturing of human extracellular vesicle-based therapeutics for clinical use. Int. J. Mol. Sci. 2017, 18, 1190. [CrossRef]

41. Whitford, W.; Guterstam, P. Exosome manufacturing status. Future Med. Chem. 2019, 11, 1225–1236. [CrossRef]

42. Mendt, M.; Kamerkar, S.; Sugimoto, H.; McAndrews, K.M.; Wu, C.C.; Gagea, M.; Yang, S.; Blanko, E.V.R.; Peng, Q.; Ma, X.; et al. Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight 2018, 3, e9263. [CrossRef]

43. Lotvall, J.; Hill, A.F.; Hochberg, F.; Buzas, E.I.; Di Vizio, D.; Gardiner, C.; Gho, Y.S.; Kurochkin, I.V.; Mathivanan, S.; Quesenberry, P.; et al. Minimal experimental requirements for definition of extracellular vesicles and their functions, a position statement from the International Society for Extracellular Vesicles. J. Extracell. Vesicles 2014, 3, 26913. [CrossRef]

44. Wittwer, K.W.; Soekmdjij, C.; Hill, A.F.; Wauben, M.H.; Buzas, E.I.; Di Vizio, D.; Falcon-Perez, J.M.; Gardiner, C.; Hochberg, F.; Kurochkin, I.V.; et al. Updating the minimal requirements for extracellular vesicle studies, building bridges to reproducibility. J. Extracell. Vesicles 2017, 6, 1396823. [CrossRef] [PubMed]

45. Thery, C.; Wittwer, K.W.; Aikawa, E.; Alcaraz, M.J.; Anderson, J.D.; Andriantsitohaina, R.; Antoniou, A.; Arab, T.; Archer, F.; Atkin-Smith, G.K.; et al. Minimal information for studies of extracellular vesicles 2018
(MISEV2018), a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J. Extracell. Vesicles* 2018, 7, 1535750. [CrossRef] [PubMed]

46. Cell and Gene Therapy Products Division, Biopharmaceutical and Herbal Medicine Evaluation Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety. Guideline on Quality, Non-Clinical and Clinical Assessment of Extracellular Vesicles Therapy Products. 2018. Available online: www.nifds.go.kr/brd/m_15/down.do?brd_id=167&seq=16265&data_tp=A&file_seq=1 (accessed on 13 December 2019).

47. Pachler, K.; Lener, T.; Streif, D.; Dunai, Z.A.; Desgeorges, A.; Feichtner, M.; Öller, M.; Schallmoser, K.; Rohde, E.; Gimona, M. A good manufacturing practice-grade standard protocol for exclusively human mesenchymal stromal cell-derived extracellular vesicles. *Cytotherapy* 2017, 19, 458–472. [CrossRef] [PubMed]

48. Andriolo, G.; Provasi, E.; Lo Cicero, V.; Brambilla, A.; Soncin, S.; Torre, T.; Milano, G.; Biemi, V.; Vassalli, G.; Turchetto, L.; et al. Exosomes from human cardiac progenitor cells for therapeutic applications, development of a GMP-grade manufacturing method. *Front. Physiol.* 2018, 9, 1169. [CrossRef] [PubMed]

49. Koritzinsky, E.H.; Street, J.M.; Star, R.A.; Yuen, P.S. Quantification of Exosome. *J. Cell. Physiol.* 2018, 232, 1587–1590. [CrossRef]

50. Sanchez, L.M.; Alvarez, V.A. Advances in magnetic noble metal/iron-based oxide hybrid nanoparticles as biomedical devices. *Bioengineering* 2019, 6, 75. [CrossRef]

51. Ramirez, M.; Amorim, M.G.; Gadelha, C.; Milic, I.; Welsh, J.A.; Freitas, V.M.; Nawaz, M.; Akbar, N.; Couch, Y.; Makin, L.; et al. Technical challenges of working with extracellular vesicles. *Nanoscale* 2018, 10, 881–906. [CrossRef]

52. Li, X.; Corbett, A.L.; Taatizadeh, E.; Tasnim, N.; Little, J.P.; Garnis, C.; Daugaard, M.; Guns, E.; Hoorfar, M.; Li, I.T.S. Challenges and opportunities in exosome research—Perspectives from biology, engineering, and cancer therapy. *APL Bioeng.* 2019, 3, 011503. [CrossRef]

53. Bachurski, D.; Schuldner, M.; Nguyen, P.H.; Malz, A.; Reiners, K.S.; Grenzi, P.C.; Babatz, F.; Schauss, A.C.; Hansen, H.P.; Hallek, M.; et al. Extracellular vesicle measurements with nanoparticle tracking analysis—an accuracy and repeatability comparison between NanoSight NS300 and ZetaView. *J. Extracell. Vesicles* 2019, 8, 1596016. [CrossRef]

54. van der Pol, E.; Coumans, F.A.; Grootemaat, A.E.; Gardiner, C.; Sargent, I.L.; Harrison, P.; Sturk, A.; van Leeuwen, T.G.; Nieuwland, R. Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. *J. Thromb. Haemost.* 2014, 12, 1182–1192. [CrossRef]

55. Vestad, B.; Llorente, A.; Neurauter, A.; Phuyal, S.; Kierulf, B.; Kierulf, P.; Skotland, T.; Sandvig, K.; Haug, K.B.F.; Ostebo, R. Size and concentration analyses of extracellular vesicles by nanoparticle tracking analysis, a variation study. *J. Extracell. Vesicles* 2017, 6, 1344087. [CrossRef] [PubMed]

56. Szatanek, R.; Baj-Krzyworzeka, M.; Zimoch, J.; Lekka, M.; Siedlar, M.; Baran, J. The methods of choice for extracellular vesicles (EVs) characterization. *Int. J. Mol. Sci.* 2017, 18, 1153. [CrossRef] [PubMed]

57. Tian, X.; Nejadnik, M.R.; Baunsgaard, D.; Henriksen, A.; Rischel, C.; Jiskoot, W. A comprehensive evaluation of nanoparticle tracking analysis (NanoSight) for characterization of proteinaceous submicron particles. *J. Pharm. Sci.* 2016, 105, 3366–3375. [CrossRef] [PubMed]

58. Carnell-Morris, P.; Tannetta, D.; Siupa, A.; Hole, P.; Dragovic, R. Analysis of extracellular vesicles using fluorescence nanoparticle tracking analysis. *Methods Mol. Biol.* 2017, 1660, 153–173. [PubMed]

59. Ma, L.; Zhu, S.; Tian, Y.; Zhang, W.; Wang, S.; Chen, C.; Wu, L.; Yan, X. Label-free analysis of single viruses with a resolution comparable to that of electron microscopy and the throughput of flow cytometry. *Angew. Chem. Int. Ed. Engl.* 2016, 55, 10239–10243. [CrossRef] [PubMed]

60. Danielson, K.M.; Estanislau, J.; Tigg, J.; Toxavidis, V.; Camacho, V.; Felton, E.J.; Khoory, J.; Kreimer, S.; Ivanov, A.R.; Mantel, P.Y.; et al. Diurnal variations of circulating extracellular vesicles measured by nano flow cytometry. *PLoS ONE* 2016, 11, e0144678. [CrossRef]

61. Nizamudeen, Z.; Markus, R.; Lodge, R.; Parmenter, C.; Platt, M.; Chakrabarti, L.; Sottile, V. Rapid and accurate analysis of stem cell-derived extracellular vesicles with super resolution microscopy and live imaging. *Biochim. Biophys. Acta. Mol. Cell. Res.* 2018, 1865, 1891–1900. [CrossRef]

62. Kabe, Y.; Suematsu, M.; Sakamoto, S.; Hirai, M.; Koike, I.; Hishiki, T.; Matsuda, A.; Hasegawa, Y.; Tsujita, K.; Ono, M.; et al. Development of a highly sensitive device for counting the number of disease-specific exosomes in human sera. *Clin. Chem.* 2018, 64, 1463–1473. [CrossRef]
63. Gorgens, A.; Bremer, M.; Ferrer-Tur, R.; Murke, F.; Tertel, T.; Horn, P.A.; Thalmann, S.; Welsh, J.A.; Probst, C.; Guerin, C.; et al. Optimisation of imaging flow cytometry for the analysis of single extracellular vesicles by using florescence-tagged vesicles as biological reference material. J. Extracell. Vesicles 2019, 8, 1597567.

64. Stuffers, S.; Sem Wegner, C.; Stenmark, H.; Brech, A. Multivesicular endosome biogenesis in the absence of ESCRTs. Traffic 2009, 10, 925–937. [CrossRef]

65. Kowal, J.; Arras, G.; Colombo, M.; Jouve, M.; Morath, J.P.; Primald-Bengtson, B.; Dingli, F.; Loew, D.; Tkach, M.; Thiery, C. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc. Nat. Acad. Sci. USA 2016, 113, E977. [CrossRef] [PubMed]

66. Lee, Y.; El Andaloussi, S.; Wood, M.J. Exosomes and microvesicles, extracellular vesicles for genetic information transfer and gene therapy. Hum. Mol. Genet. 2012, 21, R125–R134. [CrossRef] [PubMed]

67. Butler, T.A.; Paul, J.W.; Chan, E.C.; Smith, R.; Tolosa, J.M. Misleading westerns, common quantification mistakes in western blot densitometry and proposed corrective measures. Biomed. Res. Int. 2019, 2019, 5214821. [CrossRef] [PubMed]

68. Center for Biologics Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services. Guidance for Industry. Potency Tests for Cellular and Gene Therapy Products. Available online: www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm (accessed on 21 December 2019).

69. Wills, G.R.; Kourembanas, S.; Mitsialis, S.A. Toward exosome-based therapeutics, isolation, heterogeneity, and fit-for-purpose potency. Front. Cardiovasc. Med. 2017, 4, 63. [CrossRef]

70. Pacienza, N.; Lee, R.H.; Bae, E.H.; Kim, D.K.; Liu, Q.; Prockop, D.J.; Yannarelli, G. In vitro macrophage assay predicts the in vivo anti-inflammatory potential of exosomes from human mesenchymal stromal cells. Mol. Ther. Methods Clin. Dev. 2018, 13, 67–76. [CrossRef]

71. Blazquez, R.; Sanchez-Margallo, F.M.; de la Rosa, O.; Dalemans, W.; Alvarez, V.; Tarazona, R.; Casado, J.G. Immunomodulatory potential of human adipose mesenchymal stem cells derived exosomes on in vitro stimulated T cells. Front. Immunol. 2014, 5, 556. [CrossRef]

72. Conforti, A.; Scarsella, M.; Sarc, N.; Giorda, E.; Biagini, S.; Proia, A.; Carsetti, R.; Locatelli, F.; Bernardo, M.E. Microvesicles derived from mesenchymal stromal cells are not as effective as their cellular counterpart in the ability to modulate immune responses in vitro. Stem Cells Dev. 2014, 23, 2591–2599. [CrossRef]

73. Gouveia de Andrade, A.V.; Bertolino, G.; Riewaldt, J.; Bieback, K.; Karbanova, J.; Odendahl, M.; Bornhauser, M.; Schmitz, M.; Corbeil, D.; Tonn, T. Extracellular vesicles secreted by bone marrow- and adipose tissue-derived mesenchymal stromal cells fail to suppress lymphocyte proliferation. Stem Cells Dev. 2015, 24, 1374–1376. [CrossRef]

74. Zhang, J.M.; An, J. Cytokines, inflammation, and pain. Int. Anesthesiol. Clin. 2007, 45, 27–37. [CrossRef]

75. Cicchese, J.M; Evans, S.; Hult, C.; Joslyn, L.R.; Wessler, T.; Millar, J.A.; Marino, S.; Mattila, J.T.; Linderman, J.J.; et al. Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology. Immunol. Rev. 2018, 285, 147–167. [CrossRef]

76. Opal, S.M.; DePalo, V.A. Anti-inflammatory cytokines. Chest 2000, 117, 1162–1172. [CrossRef] [PubMed]

77. Inflammation. Wikipedia. Available online: en.wikipedia.org/wiki/Inflammation (accessed on 23 December 2019).

78. Inflammatory Diseases. Nature. Available online: www.nature.com/subjects/inflammatory-diseases (accessed on 23 December 2019).

79. Sugimoto, M.A.; Sousa, L.P.; Pinho, V.; Perretti, M.; Teixeira, M.M. Resolution of inflammation, what controls its onset? Front. Immunol. 2016, 7, 160. [CrossRef] [PubMed]

80. Inflammation, the Root Cause of all Disease? Available online: www.alkaway.com.au/blog/inflammation-the-root-cause-of-all-disease/ (accessed on 22 December 2019).

81. Hunter, P. The inflammation theory of disease. The growing realization that chronic inflammation is crucial in many diseases opens new avenues for treatment. EMBO Rep. 2012, 13, 968–970. [CrossRef] [PubMed]

82. Chang, C.L.; Sung, P.H.; Chen, K.H.; Shao, P.L.; Yang, C.C.; Cheng, B.C.; Lin, K.C.; Chen, C.H.; Chai, H.T.; Chang, H.W.; et al. Adipose-derived mesenchymal stem cell-derived exosomes alleviate overwhelming systemic inflammatory reaction and organ damage and improve outcome in rat sepsis syndrome. Am. J. Transl. Res. 2018, 10, 1053–1070. [PubMed]

83. Yu, B.; Zhang, X.; Li, X. Exosomes derived from mesenchymal stem cells. Int. J. Mol. Sci. 2014, 15, 4142–4157. [CrossRef]
84. Börger, V.; Bremer, M.; Ferrer-Tur, R.; Gockeln, L.; Stambouli, O.; Becic, A.; Giebel, B. Mesenchymal stem/stromal cell-derived extracellular vesicles and their potential as novel immunomodulatory therapeutic agents. *Int. J. Mol. Sci.* 2017, 18, 1450. [CrossRef]

85. He, X.; Dong, Z.; Cao, Y.; Wang, H.; Liu, S.; Liao, L.; Jin, Y.; Yuan, L.; Li, B. MSC-derived exosome promotes M2 polarization and enhances cutaneous wound healing. *Stem Cells Int.* 2019, 2019, 7132708. [CrossRef]

86. Willis, G.R.; Fernandez-Gonzalez, A.; Anastas, J.; Vitali, S.H.; Liu, X.; Ericsson, M.; Kwong, A.; Mitsialis, S.A.; Kourembanas, S. Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. *Am. J. Respir. Crit. Care Med.* 2018, 197, 104–116. [CrossRef]

87. Ti, D.; Hao, H.; Tong, C.; Liu, J.; Dong, L.; Zheng, J.; Zhao, Y.; Liu, H.; Fu, X.; Han, W. LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b. *J. Transl. Med.* 2015, 13, 308. [CrossRef]

88. Li, X.; Liu, L.; Yang, J.; Yu, Y.; Chai, J.; Wang, L.; Ma, L.; Yin, H. Exosome derived from human umbilical cord mesenchymal stem cell dedicates MiR-181c attenuating burn-induced excessive inflammation. *Ebiomedicine* 2016, 6, 72–82. [CrossRef]

89. Dalirfardouei, R.; Jamialahmadi, K.; Jafarian, A.H.; Mahdipour, E. Promising effects of exosomes isolated from menstrual blood-derived mesenchymal stem cell on wound-healing process in diabetic mouse model. *J. Tissue Eng. Regen. Med.* 2018, 13, 555–568. [CrossRef] [PubMed]

90. Li, J.; Xue, H.; Li, T.; Chu, X.; Xin, D.; Xiong, Y.; Qiu, W.; Gao, X.; Qian, M.; Xu, J.; et al. Exosomes derived from mesenchymal stem cells attenuate the progression of atherosclerosis in ApoE-/ mice via miR-let7 mediated infiltration and polarization of M2 macrophage. *Biochem. Biophys. Res. Commun.* 2019, 510, 565–572. [CrossRef] [PubMed]

91. Zhao, J.; Li, X.; Hu, J.; Chen, F.; Qiao, S.; Sun, X.; Gao, L.; Xie, J.; Xu, B. Mesenchymal stromal cell-derived exosomes attenuate myocardial ischemia-reperfusion injury through miR-182-regulated macrophage polarization. *Cardiovasc. Res.* 2019, 115, 1205–1216. [CrossRef] [PubMed]

92. Liu, H.; Liang, Z.; Wang, F.; Zhou, C.; Zheng, X.; Hu, T.; He, X.; Wu, X.; Lan, P. Exosomes from mesenchymal stromal cells reduce murine colonic inflammation via a macrophage-dependent mechanism. *JCI Insight* 2019, 4, 131273. [CrossRef]

93. Deng, S.; Zhou, X.; Ge, Z.; Song, Y.; Wang, H.; Liu, X.; Zhang, D. Exosomes from adipose-derived mesenchymal stem cells ameliorate cardiac damage after myocardial infarction by activating S1P/S1PR1 signaling and promoting macrophage M2 polarization. *Int. J. Biochem. Cell. Biol.* 2019, 114, 105564. [CrossRef]

94. Heo, J.S.; Choi, Y.; Kim, H.O. Adipose-derived mesenchymal stem cells promote M2 macrophage phenotype through exosomes. *Stem Cells Int.* 2019, 2019, 7921760. [CrossRef]

95. Zhao, H.; Shang, Q.; Pan, Z.; Bai, Y.; Li, Z.; Zhang, H.; Zhang, Q.; Guo, C.; Zhang, L.; Wang, Q. Exosomes from adipose-derived stem cells attenuate adipose inflammation and obesity through polarization M2 macrophages and beiging in white adipose tissue. *Diabetes* 2018, 67, 235–247. [CrossRef]

96. Chen, W.; Huang, Y.; Han, J.; Yu, L.; Li, Y.; Lu, Z.; Li, H.; Liu, Z.; Shi, C.; Duan, F.; et al. Immunomodulatory effects of mesenchymal stromal cells-derived exosome. *Immunol. Res.* 2016, 64, 831–840. [CrossRef]

97. Du, Y.M.; Zhuansun, Y.X.; Chen, R.; Lin, L.; Lin, Y.; Li, J.G. Mesenchymal stem cell exosomes promote immunosuppression of regulatory T cells in asthma. *Exp. Cell Res.* 2018, 363, 114–120. [CrossRef]

98. Zhang, Q.; Fu, L.; Liang, Y.; Guo, Z.; Wang, L.; Ma, C.; Wang, H. Exosomes originating from MSCs stimulated with TGF-β and IFN-γ promote Treg differentiation. *J. Cell. Physiol.* 2018, 233, 6832–6840. [CrossRef]

99. Zhang, B.; Yin, Y.; Lai, R.C.; Tan, S.S.; Choo, A.B.; Lim, S.K. Mesenchymal stem cells secrete immunologically active exosomes. *Stem Cells Dev.* 2014, 23, 1233–1244. [CrossRef] [PubMed]

100. Nojehdehi, S.; Soudi, S.; Hessampour, A.; Rasouli, S.; Soleimani, M.; Hashemi, S.M. Immunomodulatory effects of mesenchymal stem cell-derived exosomes on experimental type-1 autoimmune diabetes. *J. Cell. Biochem.* 2018, 119, 9433–9443. [CrossRef] [PubMed]

101. Riaziifar, M.; Mohammadi, M.R.; Pone, E.J.; Yari, A.; Lässer, C.; Segaliny, A.I.; McIntyre, L.L.; Shelke, G.V.; Hutchins, E.; Hamamoto, A.; et al. Stem cell-derived exosomes as nanotheapeutics for autoimmune and neurodegenerative disorders. *ACS Nano* 2019, 13, 6670–6688. [CrossRef] [PubMed]

102. Tamura, R.; Uemoto, S.; Tabata, Y. Immunosuppressive effect of mesenchymal stem cell-derived exosomes on a concanavalin A-induced liver injury model. *Inflamm. Regen.* 2016, 36, 26. [CrossRef]
103. Fattore, A.D.; Luciano, R.; Pascucci, L.; Goffredo, B.M.; Giorda, E.; Scapaticci, M.; Fierabracci, A.; Muraca, M. Immunoregulatory Effects of Mesenchymal Stem Cell-Derived Extracellular Vesicles on T Lymphocytes. *Cells* 2020, 9, 1157. [CrossRef]

104. Trapani, M.D.; Bassi, G.; Midolo, M.; Gatti, A.; Kamga, P.T.; Cassaro, A.; Carusone, R.; Adamo, A.; Krampera, M. Differential and transferable modulatory effects of mesenchymal stromal cell-derived extracellular vesicles on T, B and NK cell functions. *Sci. Rep.* 2016, 6. [CrossRef]

105. Monguíó-Tortajada, M.; Roura, S.; Gálvez-Montón, C.; Pujal, J.M.; Aran, G.; Sanjurjo, L.; Franquesa, M.; Sarrias, M.R.; Bayes-Genis, A.; Borrás, F.E. Nanosized UCMS-derived extracellular vesicles but not conditioned medium exclusively inhibit the inflammatory response of stimulated T cells, implications for nanomedicine. *Theranostics* 2017, 7, 270–284. [CrossRef]

106. Khare, D.; Or, R.; Resnick, I.; Barkatz, C.; Almogi-Hazan, O.; Avni, B. Mesenchymal stromal cell-derived exosomes affect mRNA expression and function of B-lymphocytes. *Front. Immunol.* 2018, 9, 3053. [CrossRef]

107. Hu, S.; Li, Z.; Cores, J.; Huang, K.; Su, T.; Dinh, P.U.; Cheng, K. Needle-Free Injection of Exosomes derived from human dermal fibroblast spheroids ameliorates skin photoaging. *ACS Nano* 2019, 13, 11273–11282. [CrossRef]

108. Bai, Y.; Han, Y.D.; Yan, X.L.; Ren, J.; Zeng, Q.; Li, X.D.; Pei, X.T.; Han, Y. Adipose mesenchymal stem cell-derived exosomes stimulated by hydrogen peroxide enhanced skin flap recovery in ischemia-reperfusion injury. *Biochem. Biophys. Res. Commun.* 2018, 500, 310–317. [CrossRef]

109. Shin, K.O.; Ha, D.H.; Kim, J.O.; Crumrine, D.A.; Meyer, J.M.; Kim, H.K.; Lee, J.; Kwon, H.H.; Park, G.H.; Lee, J.H.; et al. Exosomes from human adipose tissue-derived mesenchymal stem cells promote epidermal barrier repair by inducing de novo synthesis of ceramides in atopic dermatitis. *Cells* 2020, 9, 680. [CrossRef]

110. Alzahrani, F.A. Melatonin improves therapeutic potential of mesenchymal stem cells-derived exosomes against renal ischemia-reperfusion injury. *Am. J. Transl. Res.* 2019, 11, 2887–2907. [PubMed]

111. Shen, B.; Liu, J.; Zhang, F.; Wang, Y.; Qin, Y.; Zhou, Z.; Qiu, J.; Fan, Y. CCR2 Positive exosome released by mesenchymal stem cell secretions functionally suppresses macrophage functions and alleviates ischemia/reperfusion-induced renal injury. *Stem Cells Int.* 2016, 2016, 1240301. [CrossRef] [PubMed]

112. Wang, B.; Jia, H.; Zhang, B.; Wang, J.; Ji, C.; Zhu, X.; Yan, Y.; Yin, L.; Yu, J.; Qian, H.; et al. Pre-incubation with hucMSC-exosomes prevents cisplatin-induced nephrotoxicity by activating autophagy. *Stem Cell Res. Ther.* 2017, 8, 75. [CrossRef] [PubMed]

113. Bai, L.; Shao, H.; Wang, H.; Zhang, Z.; Su, C.; Dong, L.; Yu, B.; Chen, X.; Li, X.; Zhang, X. Effects of mesenchymal stem cell-derived exosomes on experimental autoimmune uveitis. *Sci. Rep.* 2017, 7, 4323. [CrossRef]

114. Bier, A.; Berenstein, P.; Kronfeld, N.; Morgoulis, D.; Ziv-Av, A.; Goldstein, H.; Kazimirsky, G.; Cazacu, S.; Meir, R.; Popovtzer, R.; et al. Placenta-derived mesenchymal stromal cells and their exosomes exert therapeutic effects in Duchenne muscular dystrophy. *Biomaterials* 2018, 174, 67–78. [CrossRef] [PubMed]

115. Chauvey, S.; Thuason, S.; Ponnalagu, D.; Alam, M.A.; Geerhaye, C.P.; Aghai, Z.; Singh, H.; Bhandari, V. Early gestational mesenchymal stem cell secretome attenuates experimental bronchopulmonary dysplasia in part via exosome-associated factor TSG-6. *Stem Cell Res. Ther.* 2018, 9, 173. [CrossRef] [PubMed]

116. Cui, G.H.; Guo, H.D.; Li, H.; Zhai, Y.; Gong, Z.B.; Wu, J.; Liu, J.S.; Dong, Y.R.; Hou, S.X.; Liu, J.R. RVG-modified exosomes derived from mesenchymal stem cells rescue memory deficits by regulating inflammatory responses in a mouse model of Alzheimer’s disease. *Immun. Ageing* 2019, 16, 10. [CrossRef]

117. Doepnner, T.R.; Herz, J.; Görgens, A.; Schlechter, J.; Ludwig, A.K.; Radtke, S.; de Miroshedji, K.; Horn, P.A.; Giebel, B.; Hermann, D.M. Extracellular vesicles improve post-stroke neuroregeneration and prevent postischemic immunosuppression. *Stem Cells Transl. Med.* 2015, 4, 1131–1143. [CrossRef]

118. Fan, B.; Li, C.; Szalad, A.; Wang, L.; Pan, W.; Zhang, R.; Chopp, M.; Zhang, Z.G.; Liu, X.S. Mesenchymal stromal cell-derived exosomes ameliorate peripheral neuropathy in a mouse model of diabetes. *Diabetologia* 2020, 63, 431–443. [CrossRef]

119. Qi, H.; Liu, D.P.; Xiao, D.W.; Tian, D.C.; Su, Y.W.; Jin, S.F. Exosomes derived from mesenchymal stem cells inhibit mitochondrial dysfunction-induced apoptosis of chondrocytes via p38, ERK, and Akt pathways. *In Vitro Cell. Dev. Biol. Anim.* 2019, 55, 203–210. [CrossRef] [PubMed]

120. Zhang, S.; Teo, K.Y.W.; Chuah, S.J.; Lai, R.C.; Lim, S.K.; Toh, W.S. MSC exosomes alleviate temporomandibular joint osteoarthritis by attenuating inflammation and restoring matrix homeostasis. *Biomaterials* 2019, 200, 35–47. [CrossRef]
121. Jin, Z.; Ren, J.; Qi, S. Human bone mesenchymal stem cells-derived exosomes overexpressing microRNA-26a-5p alleviate osteoarthritis via down-regulation of PTGS2. *Int. Immunopharmacol.* 2019, 78, 105946. [CrossRef] [PubMed]

122. Zhang, S.; Chuah, S.J.; Lai, R.C.; Hui, J.H.P.; Lim, S.K.; Toh, W.S. MSC exosomes mediate cartilage repair by enhancing proliferation, attenuating apoptosis and modulating immune reactivity. *Biomaterials* 2018, 156, 16–27. [CrossRef] [PubMed]

123. Xia, C.; Zeng, Z.; Fang, B.; Tao, M.; Gu, C.; Zheng, L.; Wang, Y.; Shi, Y.; Fang, C.; Mei, S.; et al. Mesenchymal stem cell-derived exosomes ameliorate intervertebral disc degeneration via anti-oxidant and anti-inflammatory effects. *Free Radic. Biol. Med.* 2019, 143, 1–15. [CrossRef] [PubMed]

124. Romanelli, P.; Bieler, L.; Scharler, C.; Pachler, K.; Kreutzner, C.; Zaunmair, P.; Jakubecova, D.; Mrowetz, H.; Benedetti, B.; Rivera, P.J.; et al. Extracellular vesicles can deliver anti-inflammatory and anti-scarring activities of mesenchymal stromal cells after spinal cord injury. *Front. Neurol.* 2019, 10, 1225. [CrossRef]

125. Wang, L.; Pei, S.; Han, L.; Guo, B.; Li, Y.; Duan, R.; Yao, Y.; Xue, B.; Chen, X.; Jia, Y. Mesenchymal stem cell-derived exosomes reduce A1 astrocytes via downregulation of phosphorylated NFκB p65 subunit in spinal cord injury. *Cell. Physiol. Biochem.* 2018, 50, 1535–1559. [CrossRef]

126. Liu, W.; Wang, Y.; Gong, F.; Rong, Y.; Luo, Y.; Tang, P.; Zhou, Z.; Zhou, Z.; Xu, T.; Jiang, T.; et al. Exosomes derived from bone mesenchymal stem cells repair traumatic spinal cord injury by suppressing the activation of A1 neurotoxic reactive astrocytes. *J. Neurotrauma* 2019, 36, 469–484. [CrossRef]

127. Shao, L.; Zhang, Y.; Lan, B.; Wang, J.; Zhang, Z.; Zhang, L.; Xiao, P.; Meng, Q.; Geng, Y.; Yu, X.Y.; et al. MiRNA-Sequence indicates that mesenchymal stem cells and exosomes have similar mechanism to enhance cardiac repair. *Biomed. Res. Int.* 2017, 2017, 4150705. [CrossRef]

128. Teng, X.; Chen, L.; Chen, W.; Yang, J.; Yang, Z.; Shen, Z. Mesenchymal stem cell-derived exosomes improve the microenvironment of infarcted myocardium contributing to angiogenesis and anti-inflammation. *Cell. Physiol. Biochem.* 2015, 37, 2415–2424. [CrossRef]

129. Li, Q.C.; Liang, Y.; Su, Z.B. Prophylactic treatment with MSC-derived exosomes attenuates traumatic acute lung injury in rats. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 2019, 316, L107–L1117. [CrossRef] [PubMed]

130. Xu, N.; Shao, Y.; Ye, K.; Qu, Y.; Memet, O.; He, D.; Shen, J. Mesenchymal stem cell-derived exosomes alleviate phosgene-induced acute lung injury in rats. *Inhal. Toxicol.* 2019, 31, 52–60. [CrossRef]

131. Liu, J.; Chen, T.; Lei, P.; Tang, X.; Huang, P. Exosomes released by bone marrow mesenchymal stem cells attenuate lung injury induced by intestinal ischemia reperfusion via the TLR4/NF-κB pathway. *Int. J. Med. Sci.* 2019, 16, 1238–1244. [CrossRef] [PubMed]

132. Mansouri, N.; Willis, G.R.; Fernandez-Gonzalez, A.; Reis, M.; Nassiri, S.; Mitsialis, S.A.; Kourembanas, S. Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through modulation of monocyte phenotypes. *JCI Insight* 2019, 4, 128060. [CrossRef] [PubMed]

133. Nong, K.; Wang, W.; Niu, X.; Hu, B.; Ma, C.; Bai, Y.; Wu, B.; Wang, Y.; Ai, K. Hepatoprotective effect of exosomes from human-induced pluripotent stem cell-derived mesenchymal stromal cells against hepatic ischemia-reperfusion injury in rats. *Cytotherapy* 2016, 18, 1548–1559. [CrossRef]

134. Li, T.; Yan, Y.; Wang, B.; Qian, H.; Zhang, X.; Shen, L.; Wang, M.; Zhou, Y.; Zhu, W.; Li, W.; et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. *Stem Cells Dev.* 2013, 22, 845–854. [CrossRef]

135. Liu, Y.; Lou, G.; Li, A.; Zhang, T.; Qi, J.; Ye, D.; Zheng, M.; Chen, Z. AMSC-derived exosomes alleviate lipopolysaccharide-d-galactosamine-induced acute liver failure by miR-17-mediated reduction of TXNIP/NLRP3 inflammasome activation in macrophages. *Ebiomedicine* 2018, 36, 140–150. [CrossRef]

136. Ma, Z.J.; Wang, Y.H.; Li, Z.G.; Wang, Y.; Li, B.Y.; Kang, H.Y.; Wu, X.Y. Immunosuppressive effect of exosomes from mesenchymal stromal cells in defined medium on experimental colitis. *Int. J. Stem Cells* 2019, 12, 440–448. [CrossRef]

137. Rager, T.M.; Olson, J.K.; Zhou, Y.; Wang, Y.; Besner, G.E. Exosomes secreted from bone marrow-derived mesenchymal stem cells protect the intestines from experimental necrotizing enterocolitis. *J. Pediatr. Surg.* 2016, 51, 942–947. [CrossRef]

138. Spinosa, M.; Lu, G.; Su, G.; Bontha, S.V.; Gehrau, R.; Salmon, M.D.; Smith, J.R.; Weiss, M.L.; Mas, V.R.; Upchurch, G.R., Jr.; et al. Human mesenchymal stromal cell-derived extracellular vesicles attenuate aortic aneurysm formation and macrophage activation via microRNA-147. *FASEB J.* 2018, 32, 6038–6050. [CrossRef]
139. Thomi, G.; Surbek, D.; Haesler, V.; Joerger-Messerli, M.; Schoeberlein, A. Exosomes derived from umbilical cord mesenchymal stem cells reduce microglia-mediated neuroinflammation in perinatal brain injury. *Stem Cell Res. Ther.* **2019**, *10*, 105. [CrossRef] [PubMed]

140. Thomi, G.; Joerger-Messerli, M.; Haesler, V.; Muri, L.; Surbek, D.; Schoeberlein, A. Intranasally administered exosomes from umbilical cord stem cells have preventive neuroprotective effects and contribute to functional recovery after perinatal brain injury. *Cells* **2019**, *8*, 855. [CrossRef] [PubMed]

141. Zhang, Y.; Chopp, M.; Meng, Y.; Katakowski, M.; Xin, H.; Mahmood, A.; Xiong, Y. Effect of exosomes derived from multipotent mesenchymal stromal cells on functional recovery and neurovascular plasticity in rats after traumatic brain injury. *J. Neurosurg.* **2015**, *122*, 856–867. [CrossRef] [PubMed]

142. Patel, N.A.; Moss, L.D.; Lee, J.Y.; Tajiri, N.; Acosta, S.; Hudson, C.; Parag, S.; Cooper, D.R.; Borlongan, C.V.; Bickford, P.C. Long noncoding RNA MALAT1 in exosomes derives regenerative function and modulates inflammation-linked networks following traumatic brain injury. *J. Neuroinflammation* **2018**, *15*, 204. [CrossRef] [PubMed]

143. Ophelders, D.R.; Wolfs, T.G.; Jellema, R.K.; Zwanenburg, A.; Andriessen, P.; Delhaas, T.; Ludwig, A.K.; Radtke, S.; Peters, V.; Janssen, L.; et al. Mesenchymal stromal cell-derived extracellular vesicles protect the fetal brain after hypoxia-ischemia. *Stem Cells Transl. Med.* **2016**, *5*, 754–763. [CrossRef]

144. Liang, Y.C.; Wu, Y.P.; Li, X.D.; Chen, S.H.; Ye, X.J.; Xue, X.Y.; Xu, N. TNF-α-induced exosomal miR-146a mediates mesenchymal stem cell-dependent suppression of urethral stricture. *J. Cell. Physiol.* **2019**, *234*, 23243–23255. [CrossRef]

145. Long, Q.; Upadhya, D.; Hattiangady, B.; Kim, D.K.; An, S.Y.; Shuai, B.; Prockop, D.J.; Shetty, A.K. Intranasal MSC-derived A1-exosomes ease inflammation, and prevent abnormal neurogenesis and memory dysfunction after status epilepticus. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, E3536–E3545. [CrossRef]

146. Xian, P.; Hei, Y.; Wang, R.; Wang, T.; Yang, J.; Li, J.; Di, Z.; Liu, Z.; Baskys, A.; Liu, W.; et al. Mesenchymal stem cell-derived exosomes as a nanotherapeutic agent for amelioration of inflammation-induced astrocyte alterations in mice. *Theranostics* **2019**, *9*, 5956–5975. [CrossRef]

147. Mathew, B.; Ravindran, S.; Liu, X.; Torres, L.; Chennakesavalu, M.; Huang, C.C.; Feng, L.; Zelka, R.; Lopez, J.; Sharma, M.; et al. Mesenchymal stem cell-derived extracellular vesicles and retinal ischemia-reperfusion. *Biomaterials* **2019**, *197*, 146–160. [CrossRef]

148. Yu, B.; Shao, H.; Su, C.; Jiang, Y.; Chen, X.; Bai, L.; Zhang, Y.; Li, Q.; Zhang, X.; Li, X. Exosomes derived from MSCs ameliorate retinal laser injury partially by inhibition of MCP-1. *Sci. Rep.* **2016**, *6*, 34562. [CrossRef]

149. Wang, X.; Gu, H.; Qin, D.; Yang, L.; Huang, W.; Essandoh, K.; Wang, Y.; Caldwell, C.C.; Peng, T.; Zingarelli, B.; et al. Exosomal miR-223 contributes to mesenchymal stem-cell-elicted cardioprotection in polymicrobial sepsis. *Sci. Rep.* **2015**, *5*, 13721. [CrossRef] [PubMed]

150. Wang, L.; Gu, Z.; Zhao, X.; Yang, N.; Wang, F.; Deng, A.; Zhao, S.; Luo, L.; Wei, H.; Guan, L.; et al. Extracellular vesicles released from human umbilical cord-derived mesenchymal stromal cells prevent life-threatening acute graft-versus-host disease in a mouse model of allogeneic hematopoietic stem cell transplantation. *Stem Cells Dev.* **2016**, *25*, 1874–1883. [CrossRef] [PubMed]

151. Kordelas, L.; Rebmann, V.; Ludwig, A.K.; Radtke, S.; Ruesing, J.; Doepner, T.R.; Epelle, M.; Horn, P.A.; Beelen, D.W.; Giebel, B. MSC-derived exosomes, a novel tool treat therapy-refractory graft-versus-host disease. *Leukemia* **2014**, *28*, 970–973. [CrossRef] [PubMed]

152. Murray, P.J. Macrophage polarization. *Annu. Rev. Physiol.* **2017**, *79*, 541–566. [CrossRef]

153. Zhuang, G.; Meng, C.; Guo, X.; Cheruku, P.S.; Shi, L.; Xu, H.; Li, H.; Wang, G.; Evans, A.R.; Safe, S.; et al. A novel regulator of macrophage activation, miR-223 in obesity-associated adipose tissue inflammation. *Circulation* **2012**, *125*, 2892–2903. [CrossRef]

154. Teng, G.G.; Wang, W.H.; Dai, Y.; Wang, S.J.; Chu, Y.X.; Li, J. Let-7b is involved in the inflammation and immune responses associated with *Helicobacter pylori* infection by targeting Toll-like receptor 4. *PLoS ONE* **2013**, *8*, e56709. [CrossRef]

155. Hutchinson, E.R.; Kawamoto, E.M.; Taub, D.D.; Lal, A.; Abdelmohsen, K.; Zhang, Y.; Wood, W.H.; 3rd; Lehrmann, E.; Camandola, S.; Becker, K.G.; et al. Evidence for miR-181 involvement in neuroinflammatory responses of astrocytes. *Glia* **2013**, *61*, 1018–1028. [CrossRef]

156. Zhang, L.; Li, Y.J.; Wu, X.Y.; Hong, Z.; Wei, W.S. MicroRNA-181c negatively regulates the inflammatory response in oxygen-glucose-deprived microglia by targeting Toll-like receptor 4. *J. Neurochem.* **2015**, *132*, 713–723. [CrossRef]
157. Singla, D.K.; Johnson, T.A.; Dargani, Z.T. Exosome treatment enhances anti-inflammatory M2 macrophages and reduces inflammation-induced pyroptosis in doxorubicin-induced cardiomyopathy. *Cells* 2019, 8, 1224. [CrossRef]

158. Castellani, M.L.; Felaco, P.; Galzio, R.J.; Tripodi, D.; Toniato, E.; De Lutiis, M.A.; Fulcheri, M.; Caraffa, A.; Antinolfi, P.; Tete, S.; et al. IL-31 a Th2 cytokine involved in immunity and inflammation. *Int. J. Immunopathol. Pharmacol.* 2010, 23, 709–713. [CrossRef]

159. Sehra, S.; Yao, Y.; Howell, M.D.; Nguyen, E.T.; Kansas, G.S.; Leung, D.Y.; Travers, J.B.; Kaplan, M.H. IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. *J. Immunol.* 2010, 184, 3186–3190. [CrossRef] [PubMed]

160. Hamilton, J.D.; Ungar, B.; Guttmann-Yassky, E. Drug evaluation review: Dupilumab in atopic dermatitis. *Immunotherapy* 2015, 7, 1043–1058. [CrossRef] [PubMed]

161. Dodig, S.; Cepelak, I.; Pavic, I. Hallmarks of senescence and aging. *Biochem. Med.* 2019, 29, 030501. [CrossRef] [PubMed]

162. Lopez-Otin, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. The Hallmarks of Aging. *Cell* 2013, 153, 1194–1217. [CrossRef]

163. Mchugh, D.; Gil, J. Senescence and aging: Causes, consequences, and therapeutic avenues. *J. Cell Biol.* 2017, 217, 65–77. [CrossRef]

164. Baker, D.J.; Childs, B.G.; Durik, M.; Wijers, M.E.; Sieben, C.J.; Zhong, J.; Saltness, R.A.; Jeganathan, K.B.; Verzosa, G.C.; Pezeshki, A.; et al. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. *Nature* 2016, 479, 232–236. [CrossRef]

165. Baker, D.J.; Childs, B.G.; Durik, M.; Wijers, M.E.; Sieben, C.J.; Zhong, J.; Saltness, R.A.; Jeganathan, K.B.; Verzosa, G.C.; Pezeshki, A.; et al. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. *Nature* 2016, 479, 232–236. [CrossRef]

166. Baar, M.P.; Brandt, R.M.C.; Putavet, D.A.; Klein, J.D.D.; Derks, K.W.J.; Bourgeois, B.R.; Stryeck, S.; Rijken, Y.; van Willigenburg, H.; Feijtel, D.A.; et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. *Cell* 2017, 169, 132–147. [CrossRef]

167. Farr, J.N.; Xu, M.; Weivoda, M.M.; Monroe, D.G.; Fraser, D.G.; Onken, J.L.; Negley, B.A.; Sfeir, J.G.; Ogrodnik, M.B.; Hachfeld, C.M.; et al. Targeting cellular senescence prevents age-related bone loss in mice. *Nat. Med.* 2017, 23, 1072–1079. [CrossRef] [PubMed]

168. Jeon, O.H.; Kim, C.; Laberge, R.M.; Demaria, M.; Tahod, S.; Vasserot, A.P.; Chung, J.W.; Kim, D.H.; Poon, Y.; David, N.; et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. *Nat. Med.* 2017, 23, 775–778. [CrossRef]

169. Borghesan, M.; Fafian-Labora, J.; Eleftheriadou, O.; Carpintero-Fernandez, C.; Paez-Ribes, M.; Vizcay-Barrena, G.; Swisa, A.; Bohlen, A.; Ximenez-Embun, P.; Lowe, R.; et al. Small extracellular vesicles are key regulators of non-cell autonomous intercellular communication in senescence via the interferon protein IFITM3. *Cell Rep.* 2019, 27, 3956–3971. [CrossRef] [PubMed]

170. Urbanelli, L.; Buratta, S.; Sagini, K.; Tancini, B.; Emiliani, C. Extracellular vesicles as new players in cellular senescence. *Int. J. Mol. Sci.* 2016, 17, 1408. [CrossRef] [PubMed]

171. Terlecki-Zaniewicz, L.; Lammermann, I.; Ladriere, J.; Bobbili, M.R.; Pils, V.; Schösser, M.; Weinmullner, R.; Dellago, H.; Skalicky, S.; Pum, D.; et al. Small extracellular vesicles and their miRNA cargo are anti-apoptotic members of the senescence-associated secretory phenotype. *Aging* 2018, 10, 1103–1132. [CrossRef]

172. D’Anca, M.; Fenoglio, C.; Serpente, M.; Arosio, B.; Cesari, M.; Scarpini, E.A.; Galimberti, D. Exosomes determinants of physiological aging and age-related neurodegenerative diseases. *Front. Aging Neurosci.* 2019, 11, 232. [CrossRef] [PubMed]

173. Franceschi, C.; Bonafé, M.; Valentini, S.; Olivieri, F.; Luca, M.D.; Ottaviani, E.; Benedictis, G.D. Inflamm-aging: An Evolutionary Perspective on Immunosenescence. *Ann. N. Y. Acad. Sci.* 2006, 1032, 244–254. [CrossRef] [PubMed]

174. Giunta, S. Is inflammaging an auto[in]nate immunity subclinical syndrome? *Immunity Ageing* 2006, 3, 12. [CrossRef]

175. Maggio, M.; Guralnik, J.M.; Longo, D.L.; Ferrucci, L. Interleukin-6 in Aging and Chronic Disease: A Magnificent Pathway. *J. Gerontol. Ser. A* 2006, 61, 575–584. [CrossRef]
176. Wang, X.; Bao, W.; Liu, J.; Ouyang, Y.-Y.; Wang, D.; Rong, S.; Xiao, X.; Shan, Z.-L.; Zhang, Y.; Yao, P.; et al. Inflammatory Markers and Risk of Type 2 Diabetes: A systematic review and meta-analysis. *Diabetes Care* 2012, 36, 166–175. [CrossRef]

177. Prattichizzo, F.; Nigris, V.D.; Sala, L.L.; Procopio, A.D.; Olivieri, F.; Ceriello, A. “Inflammaging” as a Druggable Target: A Senescence-Associated Secretory Phenotype—Centered View of Type 2 Diabetes. *Oxidative Med. Cell. Longev.* 2016, 2016, 1–10. [CrossRef]

178. Lehmann, B.D.; Faine, M.S.; Brooks, A.M.; McBubrey, J.A.; Renegar, R.H.; Wang, R.; Terrian, D.M. Senescence-associated exosome release from human prostate cancer cells. *Cancer. Res.* 2008, 68, 7864–7871. [CrossRef]

179. Takasugi, M.; Okada, R.; Takahashi, A.; Chen, D.V.; Watanabe, S.; Hara, E. Small extracellular vesicles secreted from senescent cells promote cancer cell proliferation through EphA2. *Nat. Commun.* 2017, 8, 15728. [CrossRef] [PubMed]

180. Eitan, E.; Green, J.; Bodogai, M.; Mode, N.A.; Baek, R.; Jorgensen, M.M.; Freeman, D.W.; Wittwer, K.W.; Zonderman, A.B.; Biragyn, A.; et al. Age-related changes in plasma extracellular vesicle characteristics and internalization by leukocytes. *Sci. Rep.* 2017, 7, 1342. [CrossRef] [PubMed]

181. Bertoldi, K.; Cechinel, L.R.; Schallengerger, B.; Corssac, G.B.; Davies, S.; Guerreiro, I.C.K.; Bello-Klein, A.; Millar, S.; Li, S.H.; et al. Cellular senescence contributes to age-dependent changes in circulating extracellular vesicle cargo and function. *Aging Cell* 2020, 19. [CrossRef]

182. Mitsuhashi, M.; Taub, D.D.; Kapogiannis, D.; Eitan, E.; Zukley, L.; Mattson, M.P.; Ferrucci, L.; Schwartz, J.B.; Goetzl, E.J. Aging enhances release of exosomal cytokine mRNAs by Aβ1-42-stimulated macrophages. *FASEB J.* 2013, 27, 5141–5150. [CrossRef]

183. Pusic, A.D.; Kraig, R.P. Youth and environmental enrichment generate serum exosomes containing miR-219 that promote CNS myelination. *Glia* 2014, 62, 284–299. [CrossRef]

184. Weilner, S.; Keider, V.; Winter, M.; Harreither, E.; Salzer, B.; Weiss, F.; Schraml, E.; Messner, P.; Pietschmann, P.; Hildner, F.; et al. Vesicular galectin-3 levels decrease with donor age and contribute to the reduced osteo-inductive potential of human plasma derived extracellular vesicles. *Aging* 2016, 8, 16–33. [CrossRef]

185. Buratta, S.; Urbanelli, L.; Sagini, K.; Giovagnoli, S.; Caponi, S.; Fioretto, D.; Mitro, N.; Caruso, D.; Emiliani, C. Extracellular vesicles released by fibroblasts undergoing H-Ras induced senescence show changes in lipid profile. *PloS ONE* 2017, 12, e0188840. [CrossRef]

186. Takasugi, M. Emerging roles of extracellular vesicles in cellular senescence and aging. *Aging Cell* 2018, 17, e12734. [CrossRef]

187. Khayrullin, A.; Krishnan, P.; Martinez-Nater, L.; Mendhe, B.; Fulzele, S.; Liu, Y.; Mattison, J.A.; Hamrick, M.W. Very long-chain C24,1 ceramide is increased in serum extracellular vesicles with aging and can induce senescence in bone-derived mesenchymal stem cells. *Cells* 2019, 8, 37. [CrossRef]

188. Mobarak, H.; Heidarpour, M.; Lolicato, F.; Nouri, M.; Rahbarghazi, R.; Mahdipour, M. Physiological impact of extracellular vesicles on female reproductive system, highlights to possible restorative effects on female-age-related fertility. *Biofactors* 2019, 45, 293–303. [CrossRef] [PubMed]

189. Davis, C.; Dukes, A.; Drewry, M.; Helwa, I.; Johnson, M.H.; Isales, C.M.; Hill, W.D.; Liu, Y.; Shi, X.; Fulzele, S.; et al. MicroRNA-183-5p increases with age in bone-derived extracellular vesicles, suppresses bone marrow stromal (stem) cell proliferation, and induces stem cell senescence. *Tissue Eng. Part A* 2017, 23, 1231–1340. [CrossRef] [PubMed]

190. Dong, C.; Zhou, Q.; Fu, T.; Zhao, R.; Yang, J.; Kong, X.; Zhang, Z.; Sun, C.; Bao, Y.; Ge, X.; et al. Circulating exosomes derived-miR-146a from systemic lupus erythematosus patients regulates senescence of mesenchymal stem cells. *Biomed. Res. Int.* 2019, 2019, 6071308. [CrossRef] [PubMed]

191. Jeon, O.H.; Wilson, D.R.; Clement, C.C.; Rathod, S.; Cherry, C.; Powell, B.; Lee, Z.; Khalil, A.M.; Green, J.J.; Campisi, J.; et al. Senescence cell-associated extracellular vesicles serve as osteoarthritis disease and therapeutic markers. *JCI Insight* 2019, 4, e125019. [CrossRef] [PubMed]

192. Khalifa, A.; Marín, J.M.; Qiao, Z.; Rubio, D.S.; Kheirandish-Gozal, L.; Gozal, D. Plasma exosomes in OSA patients promote endothelial senescence, effect of long-term adherent continuous positive airway pressure. *Sleep* 2019, zsz217. [CrossRef]
194. Menon, R. Initiation of human parturition, signaling from senescent fetal tissues via extracellular vesicle mediated paracrine mechanism. *Obstet. Gynecol. Sci.* 2019, 62, 199–211. [CrossRef]
195. Wong, P.F.; Tong, K.L.; Jamal, J.; Khor, E.S.; Lai, S.L.; Mustafa, M.R. Senescent HUVECs-secreted exosomes trigger endothelial barrier dysfunction in young endothelial cells. *Excliq* 2019, 18, 764–776.
196. Cao, Q.; Guo, Z.; Yan, Y.; Wu, J.; Song, C. Exosomal long noncoding RNAs in aging and age-related diseases. *Iwmb Life* 2019, 71, 1846–1856. [CrossRef]
197. Borrelli, C.; Ricci, B.; Vulpis, E.; Fionda, C.; Ricciardi, M.R.; Petrucci, M.T.; Masuelli, L.; Peri, A.; Cippitelli, M.; Zingoni, A.; et al. Drug-induced senescent multiple myeloma cells elicit NK cell proliferation by direct or exosome-mediated IL15 trans-presentation. *Cancer Immunol. Res.* 2018, 6, 860–869. [CrossRef]
198. Ruan, Y.; Lin, N.; Ma, Q.; Chen, R.; Zhang, Z.; Wen, W.; Chen, H.; Sun, J. Circulating IncRNAs Analysis in Patients with Type 2 Diabetes Reveals Novel Genes Influencing Glucose Metabolism and Islet β-Cell Function. *Cell. Physiol. Biochem.* 2018, 46, 335–350. [CrossRef]
199. Cao, Q.; Guo, Z.; Chen, W.; Zheng, P.; Zeng, J.; Tong, W. Exosomal lncRNA GAS5 regulates the apoptosis of macrophages and vascular endothelial cells in atherosclerosis. *PLoS ONE* 2017, 12, e0185406. [CrossRef]
200. Chen, L.; Yang, W.; Guo, Y.; Chen, W.; Cao, Q.; Guo, Z.; Yan, Y.; Wu, J.; Song, C. Exosomal long noncoding RNAs in aging and age-related diseases. *J. Exclij* 2019, 8, 1. [CrossRef] [PubMed]
201. Yoshida, M.; Satoh, A.; Lin, J.B.; Mills, K.F.; Sasaki, Y.; Rensing, N.; Wong, M.; Apte, R.S.; Imai, S.I. Extracellular vesicle-contained eNAMPT delays aging and extends lifespan in mice. *Cell Metab.* 2019, 30, 329–342. [CrossRef] [PubMed]
202. Lee, B.R.; Kim, J.H.; Choi, E.S.; Cho, J.H.; Kim, E. Effects of young exosomes injected in aged mice. *Int. J. Nanomed.* 2018, 13, 5335–5345. [CrossRef] [PubMed]
203. Wang, W.; Wang, L.; Ruan, L.; Oh, J.; Dong, X.; Zhuge, Q.; Su, D.M. Extracellular vesicles extracted from young donor serum attenuated inflammaging via partially rejuvenating aged T-cell immunotolerance. *FASEB J.* 2018, 32, 5335–5345. [CrossRef] [PubMed]
204. Zhang, Y.; Kim, M.S.; Jia, B.; Yan, J.; Sun, J. Circulating IncRNAs Analysis in Patients with Type 2 Diabetes Reveals Novel Genes Influencing Glucose Metabolism and Islet β-Cell Function. *Cell. Physiol. Biochem.* 2018, 46, 335–350. [CrossRef] [PubMed]
205. Wang, W.; Wang, L.; Ruan, L.; Oh, J.; Dong, X.; Zhuge, Q.; Su, D.M. Extracellular vesicles extracted from young donor serum attenuated inflammaging via partially rejuvenating aged T-cell immunotolerance. *FASEB J.* 2018, 32, 5335–5345. [CrossRef] [PubMed]
206. Zhu, B.; Zhang, L.; Liang, C.; Liu, B.; Pan, X.; Wang, Y.; Zhang, Y.; Zhang, Y.; Xie, W.; Yan, B.; et al. Stem cell-derived exosomes prevent aging-induced cardiac dysfunction through a novel exosome-lncRNA MALAT1/NK-xB/TNF-α signaling pathway. *Oxid. Med. Cell. Longev.* 2019, 2019, 9739258. [CrossRef]
207. Han, C.; Zhou, J.; Liu, B.; Liang, C.; Pan, X.; Zhang, Y.; Zhang, Y.; Wang, Y.; Shao, L.; Zhu, B.; et al. Delivery of miR-675 by stem cell-derived exosomes encapsulated in silk fibroin hydrogel prevents aging-induced vascular dysfunction in mouse hindlimb. *Mater. Sci. Eng. C Mater. Biol. Appl.* 2019, 99, 322–332. [CrossRef]
208. Liu, S.; Mahairaki, V.; Bai, H.; Ding, Z.; Li, J.; Witter, K.W.; Cheng, L. Highly purified human extracellular vesicles produced by induced adult stem cells alleviate aging cellular phenotypes of senescent human cells. *Stem Cells* 2019, 37, 779–790. [CrossRef]
209. Tofino-Vian, M.; Guilhen, M.I.; del Caz, M.D.P.; Castejon, M.A.; Alcaraz, M.J. Extracellular vesicles from adipose-derived mesenchymal stem cells downregulate senescence features in osteoarthritic osteoblasts. *Oxid. Med. Cell. Longev.* 2017, 2017, 7197598. [CrossRef] [PubMed]
210. Zuo, R.; Liu, M.; Wang, Y.; Li, J.; Wang, W.; Wu, J.; Sun, C.; Li, B.; Wang, Z.; Lan, W.; et al. BM-MSC-derived exosomes alleviate radiation-induced bone loss by restoring the function of recipient BM-MSCs and activating Wnt/β-catenin signaling. *Stem Cell Res. Ther.* 2019, 10, 30. [CrossRef] [PubMed]
211. Bae, Y.U.; Song, Y.; Kim, C.H.; Kim, K.S.; Hyn, S.H.; Jee, B.A.; Choi, J.H.; Sung, H.K.; Choi, H.C.; et al. Embryonic stem cell-derived mmu-miR-291a-3p inhibits cellular senescence in human dermal fibroblasts through the TGF-β receptor 2 pathway. *J. Gerontol. A Biol. Sci. Med. Sci.* 2019, 74, 1359–1367. [CrossRef] [PubMed]
212. Chen, B.; Sun, Y.; Zhang, J.; Zhu, Q.; Sun, J.; Niu, X.; Deng, Z.; Li, Q.; Wang, Y. Human embryonic stem cell-derived exosomes promote pressure ulcer healing in aged mice by rejuvenating senescent endothelial cells. *Stem Cell Res. Ther.* 2019, 10, 142. [CrossRef]
213. Oh, M.; Lee, J.; Kim, Y.J.; Rhee, W.J.; Park, J.H. Exosomes derived from human induced pluripotent stem cells ameliorate the aging of skin fibroblasts. *Int. J. Mol. Sci.* 2018, 19, 1715. [CrossRef]

214. Ding, Q.; Sun, R.; Wang, P.; Zhang, H.; Xiang, M.; Meng, D.; Sun, N.; Chen, A.F.; Chen, S. Protective effects of human induced pluripotent stem cell-derived exosomes on high glucose-induced injury in human endothelial cells. *Exp. Ther. Med.* 2018, 15, 4791–4797. [CrossRef]

215. Yang, C.; Lim, W.; Park, J.; Park, S.; You, S.; Song, G. Anti-inflammatory effects of mesenchymal stem cell-derived exosomal microRNA-146a-5p and microRNA-548e-5p on human trophoblast cells. *Mol. Hum. Reprod.* 2019, 25, 755–771. [CrossRef]

216. van Balkom, B.W.M.; de Jong, O.G.; Smits, M.; Brummelman, J.; den Ouden, K.; de Bree, P.M.; van Eijndhoven, M.A.J.; Pegtel, D.M.; Stoorvogel, W.; Wurdinger, T.; et al. Endothelial cells require miR-214 to secrete exosomes that suppress senescence and induce angiogenesis in human and mouse endothelial cells. *Blood* 2013, 121, 3997–4006. [CrossRef]

217. Vomund, S.; Schafer, A.; Parnham, M.J.; Brune, B.; von Knethen, A. Nrf2, the master regulator of anti-oxidative responses. *Int. J. Mol. Sci.* 2017, 18, 2772. [CrossRef]

218. Banfai, K.; Garai, K.; Ernszt, D.; Pongracz, J.E.; Kvell, K. Transgenic exosomes for thymus regeneration. *Front. Immunol.* 2019, 10, 862. [CrossRef] [PubMed]

219. Jarbrink, K.; Ni, G.; Sonnergren, H.; Schmidtchen, A.; Pang, C.; Bajapai, R.; Car, J. Prevalence and incidence of wounds. *Wound.* Wikipedia. Available online: en.wikipedia.org/wiki/Wound (accessed on 21 December 2019).

220. Lazarus, G.S.; Cooper, D.M.; Knighton, D.R.; Margolis, D.J.; Pecoraro, R.E.; Rodeheaver, G.; Robson, M.C. Definitions and guidelines for assessment of wounds and evaluation of healing. *Arch. Dermatol.* 1994, 130, 489–493. [CrossRef] [PubMed]

221. Vomund, S.; Schafer, A.; Parnham, M.J.; Brune, B.; von Knethen, A. Nrf2, the master regulator of anti-oxidative responses. *Int. J. Mol. Sci.* 2017, 18, 2772. [CrossRef] [PubMed]

222. Ruben, B. Wound Healing, Reasons Wounds will not Heal. *WoundSource.* Available online: www.woundsource.com/blog/wound-healing-reasons-wounds-will-not-heal (accessed on 21 December 2019).

223. Igbal, A.; Jan, A.; Wajid, M.A.; Tariq, S. Management of chronic non-healing wounds by hirudotherapy. *Worldj. Plat. Surg.* 2017, 6, 9–17.

224. Karppinen, S.M.; Heljasvaara, R.; Gullberg, D.; Tasanen, K.; Pihlajaniemi, T. Toward understanding scarless skin wound healing and pathological scarring. *F1000Research* 2019, 8. F1000 Faculty Rev-787. [CrossRef] [PubMed]

225. Sen, C.K. Human wounds and its burden, an updated compendium of estimates. *Adv. Wound Care* 2019, 8, 38–48. [CrossRef]

226. Ferreira, A.D.F.; Gomes, D.A. Stem cell extracellular vesicles in skin repair. *Bioengineering* 2018, 6, 4. [CrossRef]

227. Kasuya, A.; Tokura, Y. Attempts to accelerate wound healing. *J. Dermal. Sci.* 2014, 76, 169–172. [CrossRef]

228. Kawasumi, A.; Sagawa, N.; Hayashi, S.; Yokoyama, H.; Tamura, K. Wound healing in mammals and amphibians, toward limb regeneration in mammals. *Curr. Top. Microbiol. Immunol.* 2013, 367, 33–49.

229. Sanchez, E.; Tilkorn, D.J.; Hager, S.; Hauser, J.; Mirastchijski, U. Skin wound healing, an update on the current knowledge and concepts. *Eur. Surg. Res.* 2017, 58, 81–94. [CrossRef]

230. Santoro, M.M.; Gaudino, G. Cellular and molecular facets of keratinocyte reepithelialization during wound healing. *Exp. Cell. Res.* 2005, 304, 274–286. [CrossRef]

231. Svolacchia, F.; De Francesco, F.; Trovato, L.; Graziano, A.; Ferraro, G.A. An innovative regenerative treatment of scars with dermal micrografts. *J. Cosmet. Dermatol.* 2016, 15, 245–253. [CrossRef] [PubMed]

232. Pelizzoz, G.; Cunha, P.S.; Carregal, V.M.; da Silva, P.S.; de Miranda, M.; Kunrath-Limam, M.; de Melo, M.I.A.; Faraco, C.C.F.; Barbosa, J.L. Extracellular vesicles from adipose-derived mesenchymal stem/stromal cells accelerate migration and activate AKT pathway in human keratinocytes and fibroblasts independently of miR-205 activity. *Stem. Cells. Int.* 2017, 2017, 9840135. [CrossRef] [PubMed]

233. Hu, L.; Wang, J.; Zhou, X.; Xiong, Z.; Zhao, J.; Yu, R.; Huang, F.; Zhang, H.; Chen, L. Exosomes derived from human adipose mesenchymal stem cells accelerates cutaneous wound healing via optimizing the characteristics of fibroblasts. *Sci. Rep.* 2016, 6, 32993. [CrossRef]
235. Wang, L.; Hu, L.; Zhou, X.; Xiong, Z.; Zhang, C.; Shehada, H.M.A.; Hu, B.; Song, J.; Chen, L. Exosomes secreted by human adipose mesenchymal stem cells promote scarless cutaneous repair by regulating extracellular matrix remodeling. Sci. Rep. 2017, 7, 13321. [CrossRef] [PubMed]

236. Wang, X.; Jiao, Y.; Pan, Y.; Zhang, L.; Gong, H.; Qi, Y.; Wang, M.; Gong, H.; Shao, M.; Wang, X.; et al. Fetal dermal mesenchymal stem cell-derived exosomes accelerate cutaneous wound healing by activating Notch signaling. Stem Cells Int. 2019, 2019, 2402916. [CrossRef]

237. Zhang, B.; Wang, M.; Gong, A.; Zhang, X.; Wu, X.; Zhu, Y.; Shi, H.; Wu, L.; Zhu, W.; Qian, H.; et al. HucMSC-exosome mediated-Wnt4 signaling is required for cutaneous wound healing. Stem Cells 2015, 33, 2158–2168. [CrossRef]

238. Sung, D.K.; Chang, Y.W.; Sung, S.I.; Park, W.S. Thrombin preconditioning of extracellular vesicles derived from mesenchymal stem cells accelerates cutaneous wound healing by boosting their biogenesis and enriching cargo content. J. Clin. Med. 2019, 8, 533. [CrossRef]

239. Zhang, B.; Wu, X.; Zhang, X.; Sun, Y.; Yan, Y.; Shi, H.; Zhu, Y.; Wu, L.; Pan, Z.; Zhu, W.; et al. Human umbilical cord mesenchymal stem cell exosomes enhance angiogenesis through the Wnt4/β-catenin pathway. Stem Cells Transl. Med. 2015, 4, 513–522. [CrossRef]

240. Zhang, J.; Guan, J.; Niu, X.; Hu, G.; Guo, S.; Li, Q.; Xie, Z.; Zhang, C.; Wang, Y. Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis. J. Transl. Med. 2015, 13, 49. [CrossRef]

241. Fang, S.; Xu, C.; Zhang, Y.; Xue, C.; Yang, C.; Bi, H.; Qian, X.; Wu, M.; Ji, K.; Zhao, Y.; et al. Umbilical cord-derived mesenchymal stem cell-derived exosomal microRNAs suppress myofibroblast differentiation by inhibiting the transforming growth factor-β/SMAD2 pathway during wound healing. Stem Cells Transl. Med. 2016, 5, 1425–1439. [CrossRef] [PubMed]

242. Shi, Q.; Qian, Z.; Liu, D.; Sun, J.; Wang, X.; Liu, H.; Xu, J.; Guo, X. GMSC-derived exosomes combined with a chitosan/silk hydrogel sponge accelerates wound healing in a diabetic rat skin defect model. Front. Physiol. 2017, 8, 904. [CrossRef] [PubMed]

243. El-Tookhy, M.S.; Shamaa, A.A.; Shehab, G.G.; Abdallah, A.N.; Azzam, O.M. Histological evaluation of experimentally induced critical size defect skin wounds using exosomal solution of mesenchymal stem cells derived microvesicles. Int. J. Stem Cells 2017, 10, 144–153. [CrossRef] [PubMed]

244. Silachev, D.N.; Goryunov, K.V.; Shpilyuk, M.A.; Beznoschenko, O.S.; Morozova, N.Y.; Kraevaya, E.E.; Popkov, V.A.; Pevzner, I.B.; Zorova, L.D.; Evtushenko, E.A.; et al. Effect of MSCs and MSC-derived extracellular vesicles on human blood coagulation. Cells 2019, 8, 258. [CrossRef]

245. Xue, M.; Jackson, C.J. Extracellular matrix reorganization during wound healing and its impact on abnormal scarring. Adv. Wound Care 2015, 4, 119–136. [CrossRef]

246. Eming, S.A.; Krieg, T.; Davidson, J.M. Inflammation in wound repair, molecular and cellular mechanisms. J. Investig. Dermatol. 2007, 127, 514–525. [CrossRef]

247. Landén, N.X.; Li, D.; Stähle, M. Transition from inflammation to proliferation, a critical step during wound healing. Cell. Mol. Life Sci. 2013, 70, 3861–3885. [CrossRef]

248. Hesketh, M.; Sahin, K.B.; West, Z.E.; Murray, R.Z. Macrophage phenotypes regulate scar formation and chronic wound healing. Int. J. Mol. Sci. 2017, 18, 1545. [CrossRef]

249. Krzyszczyk, P.; Schloss, R.; Palmer, A.; Berthiaume, F. The role of macrophages in acute and chronic wound healing and interventions to promote pro-wound healing phenotypes. Front. Physiol. 2018, 9, 419. [CrossRef]

250. Shabbir, A.; Cox, A.; Rodriguez-Menocal, L.; Salgado, M.; van Badiavas, E. Mesenchymal stem cell exosomes induce proliferation and migration of normal and chronic wound fibroblasts, and enhance angiogenesis in vitro. Stem Cells Dev. 2015, 24, 1635–1647. [CrossRef]

251. Kim, S.; Lee, S.K.; Kim, H.; Kim, T.N. Exosomes secreted from induced pluripotent stem cell-derived mesenchymal stem cells accelerate skin proliferation. Int. J. Mol. Sci. 2018, 19, 3119. [CrossRef] [PubMed]

252. Liang, X.; Zhang, L.; Wang, S.; Han, Q.; Zhao, R.C. Exosomes secreted by mesenchymal stem cells promote endothelial cell angiogenesis by transferring miR-125a. J. Cell. Sci. 2016, 129, 2182–2189. [CrossRef] [PubMed]

253. Nooshabadi, V.T.; Verdi, J.; Ebrahimi-Barough, S.; Mowla, J.; Ali Atlasi, M.; Mazoochi, T.; Valipour, E.; Shafiei, S.; Ai, J.; Banafshe, H.R. Endometrial mesenchymal stem cell-derived exosome promote endothelial cell angiogenesis in a dose dependent manner, a new perspective on regenerative medicine and cell-free therapy. Arch. Neurosci. 2019, 6, e94041.
254. McCarty, S.M.; Percival, S.L. Proteases and delayed wound healing. *Adv. Wound Care* 2013, 2, 438–447. [CrossRef] [PubMed]

255. Sabino, F.; Auf dem Keller, U. Matrix metalloproteinases in impaired wound healing. *Metalloproteinases Med.* 2015, 2, 1–8.

256. Westby, M.J.; Dumville, J.C.; Stubbs, N.; Norman, G.; Wong, J.K.; Cullum, N.; Riley, R.D. Protease activity as a prognostic factor for wound healing in venous leg ulcers. *Cochrane Database Syst. Rev.* 2018, 9, CD012841. [CrossRef]

257. International Consensus. *The Role of Proteases in Wound Healing Diagnostics; An Expert Working Group Review; Wounds International: London, UK, 2011.*

258. Lobmann, R.; Schultz, G.; Lehner, H. Proteases and the diabetic foot syndrome, mechanisms and therapeutic implications. *Diabetes Care* 2005, 28, 461–471. [CrossRef]

259. Ma, C.; Hernandez, M.A.; Kirkpatrick, V.E.; Liang, L.J.; Nouvong, A.L.; Gordon, I.I. Topical platelet-derived growth factor vs placebo therapy of diabetic foot ulcers offloaded with windowed casts, a randomized, controlled trial. *Wounds* 2015, 27, 83–91.

260. Stacey, M. Combined topical growth factor and protease inhibitor in chronic wound healing, protocol for a randomized controlled proof-of-concept study. *JMIR Res. Protoc.* 2018, 7, e97. [CrossRef]

261. Longattie, A.; Shindler, C.; Collinson, A.; Jenkinson, L.; Matthews, C.; Fitzpatrick, L.; Blundy, M.; Minter, R.; Vaughan, T.; Shwa, M.; et al. High affinity single-chain variable fragments are specific and versatile targeting motifs for extracellular vesicles. *Nanoscale* 2018, 10, 14230–14244. [CrossRef]

262. Charoenviriyakul, C.; Takahashi, T.; Morishita, M.; Nishikawa, M.; Takakura, Y. Role of extracellular vesicle surface proteins in the pharmacokinetics of extracellular vesicles. *Mol. Pharm.* 2018, 15, 1073–1080. [CrossRef] [PubMed]

263. Boeringer, T.; Gould, L.J.; Koria, P. Protease-resistant growth factor formulations for the healing of chronic wounds. *Adv. Wound Care* 2019. [CrossRef]

264. Wang, J.F.; Olson, M.E.; Reno, C.R.; Kulyk, W.; Wright, J.B.; Hart, D.A. Molecular and cell biology of skin wound healing in a pig model. *Connect. Tissue Res.* 2000, 41, 195–211. [CrossRef]

265. Sullivan, T.P.; Eaglstein, W.H.; Davis, S.C.; Mertz, P. The pig as a model for human wound healing. *Wound Repair Regen.* 2001, 9, 66–76. [CrossRef]

266. Seaton, M.; Hocking, A.; Gibran, N.S. Porcine models of cutaneous wound healing. *ILAR J.* 2015, 56, 127–138. [CrossRef]

267. Jung, Y.; Son, D.; Kwon, S.; Kim, J.; Han, K. Experimental pig model of clinically relevant wound healing delay by intrinsic factors. *Int. Wound J.* 2013, 10, 295–305. [CrossRef]

268. Grada, A.; Mervis, J.; Falanga, V. Research techniques made simple, animal models of wound healing. *J. Investig. Dermatol.* 2018, 138, 2095–2105. [CrossRef] [PubMed]

269. Eun, S.C. Stem cell and research in plastic surgery. *J. Kor. Med. Sci.* 2014, 29, S167–S169. [CrossRef] [PubMed]

270. Wang, Y.; Sun, Y.; Yang, X.Y.; Ji, S.Z.; Han, S.; Xia, Z.F. Mobilised bone marrow-derived cells accelerate wound healing. *Int. Wound J.* 2012, 10, 479. [CrossRef]

271. Castella, M.A.; Mosna, F.; Micheletti, A.; Lisi, V.; Tamassia, N.; Cont, C.; Calzetti, F.; Pelletier, M.; Pizzolo, G.; Krampera, M. Toll-like receptor-3-activated human mesenchymal stromal cells significantly prolong the survival and function of neutrophils. *Stem Cells* 2011, 29, 1001–1011. [CrossRef]

272. Faulknor, R.A.; Olekson, M.A.; Ekwueme, E.C.; Krzyszczczyk, P.; Freeman, J.W.; Berthiaume, F. Hypoxia impairs mesenchymal stromal cell-induced macrophage M1 to M2. *Technology* 2017, 5, 81–86. [CrossRef] [PubMed]

273. Waterman, R.S.; Tomchuck, S.L.; Henkle, S.L.; Betancourt, A.M. A new mesenchymal stem cell (MSC) paradigm, polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. *PLoS ONE* 2010, 5, e10088. [CrossRef] [PubMed]

274. Kalinina, N.; Khramlampieva, D.; Loguinova, M.; Butenko, I.; Pobeguts, O.; Efimenko, A.; Ageeva, L.; Sharonov, G.; Ischenko, D.; Alekseev, D.; et al. Characterization of secretomes provides evidence for adipose-derived mesenchymal stromal cells subtypes. *Stem Cell Res. Ther.* 2015, 6, 221. [CrossRef] [PubMed]

275. Sukho, P.; Hesselink, J.W.; Kops, N.; Kirpensteijn, J.; Verseijden, F.; Bastiaansen-Jenniskens, Y.M. Human mesenchymal stromal cell sheets induce macrophages predominantly to an anti-inflammatory phenotype. *Stem Cells Dev.* 2018, 27, 922–934. [CrossRef] [PubMed]

276. Alonso, L.; Fuchs, E. The hair cycle. *J. Cell. Sci.* 2006, 119, 391–393. [CrossRef] [PubMed]
277. Schneider, M.R.; Schmidt-Ullrich, R.; Paus, R. The hair follicle as a dynamic miniorgan. *Curr. Biol.* **2009**, *19*, R132–R142. [CrossRef]

278. Festa, E.; Fretz, J.; Berry, R.; Schmidt, B.; Rodeheffer, M.; Horowitz, M.; Horsley, V. Adipocyte Lineage Cells Contribute to the Skin Stem Cell Niche to Drive Hair Cycling. *Cell* **2011**, *146*, 761–771. [CrossRef]

279. Won, C.H.; Yoo, H.G.; Kwon, O.S.; Sung, M.Y.; Kang, Y.J.; Chung, J.H.; Park, B.S.; Sung, J.-H.; Kim, W.S.; Kim, K.H. Hair growth promoting effects of adipose tissue-derived stem cells. *J. Dermatol. Sci.* **2010**, *57*, 134–137. [CrossRef]

280. Huang, C.-F.; Chang, Y.-J.; Hsueh, Y.-Y.; Huang, C.-W.; Wang, D.-H.; Huang, T.-C.; Wu, Y.-T.; Su, F.-C.; Hughes, M.; Chuong, C.-M.; et al. Assembling Composite Dermal Papilla Spheres with Adipose-derived Stem Cells to Enhance Hair Follicle Induction. *Sci. Rep.* **2016**, *6*, 26436.

281. Fukuoka, H.; Narita, K.; Suga, H. Hair Regeneration Therapy: Application of Adipose-Derived Stem Cells. *Curr. Stem Cell Res. Ther.* **2017**, *12*, 531. [CrossRef]

282. Hébert, J.M.; Rosenquist, T.; Götz, J.; Martin, G.R. FGF5 as a regulator of the hair growth cycle, Evidence from targeted and spontaneous mutations. *Cell* **1994**, *78*, 1017–1025. [CrossRef]

283. Yoon, S.Y.; Kim, K.-T.; Jo, S.J.; Cho, A.-R.; Jeon, S.-I.; Choi, H.-D.; Kim, K.H.; Park, G.S.; Pack, J.K.; Kwon, O.S.; et al. Induction of hair growth by insulin-like growth factor-1 in 1,763 MHz radiofrequency-irradiated hair follicle cells. *PLoS ONE* **2011**, *6*, e28474. [CrossRef]

284. Trüeb, R.; Rezende, H.; Dias, M.R.G. A comment on the science of hair aging. *Int. J. Trichol.* **2018**, *10*, 245. [CrossRef]

285. Horev, L. Environmental and cosmetic factors in hair loss and destruction. *Curr. Probl. Dermatol.* **2007**, *35*, 103–117.

286. Hagenaaars, S.P.; Hill, W.D.; Harris, S.E.; Ritchie, S.J.; Davies, G.; Liewald, D.C.; Gale, C.R.; Porteous, D.J.; Deary, I.J.; Marioni, R.E. Genetic prediction of male pattern baldness. *PLoS Genet.* **2017**, *13*, e1006594. [CrossRef]

287. Mysore, V. Finasteride and sexual side effects. *Indian Dermatol. Online J.* **2012**, *3*, 62. [CrossRef]

288. Suchonwanit, P.; Thammarucha, S.; Leerunyakul, K. Minoxidil and its use in hair disorders, a review. *Drug Des. Devel. Ther.* **2019**, *13*, 2777–2786. [CrossRef]

289. Kerure, A.; Patwardhan, N. Complications in hair transplantation. *J. Cutan. Aesthet. Surg.* **2018**, *11*, 182. [CrossRef]

290. Zhou, L.; Wang, H.; Jing, J.; Yu, L.; Wu, X.; Lu, Z. Regulation of hair follicle development by exosomes derived from dermal papilla cells. *Biochem. Biophys. Res. Commun.* **2018**, *500*, 325–332. [CrossRef] [PubMed]

291. Kwack, M.H.; Seo, C.H.; Gangadaran, P.; Ahn, B.C.; Kim, M.K.; Kim, J.C.; Sung, Y.K. Exosomes derived from human dermal papilla cells promote hair growth in cultured human hair follicles and augment the hair-inductive capacity of cultured dermal papilla spheres. *Exp. Dermatol.* **2019**, *28*, 854–857. [CrossRef] [PubMed]

292. Yan, H.; Gao, Y.; Ding, Q.; Liu, J.; Li, Y.; Jin, M.; Xu, H.; Ma, S.; Wang, X.; Zeng, W.; et al. Exosomal Micro RNAs Derived from Dermal Papilla Cells Mediate Hair Follicle Stem Cell Proliferation and Differentiation. *Int. J. Biol. Sci.* **2019**, *15*, 1368–1382. [CrossRef] [PubMed]

293. Shi, H.; Xu, X.; Zhang, B.; Xu, J.; Pan, Z.; Gong, A.; Zhang, X.; Li, R.; Sun, Y.; Yan, Y.; et al. 3,3′-Diindolylmethane stimulates exosomal Wnt11 autocrine signaling in human umbilical cord mesenchymal stem cells to enhance wound healing. *Theranostics* **2017**, *7*, 1674–1688. [CrossRef]

294. Rajendran, R.L.; Gangadaran, P.; Bak, S.S.; Oh, J.M.; Kalimuthu, S.; Lee, H.W.; Baek, S.H.; Zhu, L.; Sung, Y.K.; Jeong, S.Y.; et al. Extracellular vesicles derived from MSCs activates dermal papilla cell in vitro and promotes hair follicle conversion from telogen to anagen in mice. *Sci. Rep.* **2017**, *7*, 15560.

295. Trüeb, R.M. Further clinical evidence for the effect of IGF-1 on hair growth and alopecia. *Ski. Appendage Disord.* **2017**, *4*, 90–95. [CrossRef]

296. Yano, K.; Brown, L.F.; Detmar, M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. *J. Clin. Investig.* **2001**, *107*, 409–417. [CrossRef]
299. Grice, E.A.; Kong, H.H.; Conlan, S.; Deming, C.B.; Davis, J.; Young, A.C.; NISC Comparative Sequencing Program; Bouffard, G.G.; Blakesley, R.W. Topographical and temporal diversity of the human skin microbiome. *Science* 2009, 324, 1190–1192. [CrossRef]

300. Fore, J. A review of skin and the effects of aging on skin structure and function. *Ostomy Wound Manag.* 2006, 52, 24–35.

301. Human Skin. Wikipedia. Available online: en.wikipedia.org/wiki/Human_skin (accessed on 19 December 2019).

302. Eyerich, S.; Eyerich, K.; Traidl-Hoffmann, C.; Biedermann, T. Cutaneous barriers and skin immunity, differentiating a connected network. *Trends Immunol.* 2018, 39, 315–327. [CrossRef]

303. Byrd, A.L.; Belkaid, Y.; Segre, J.A. The human skin microbiome. *Nat. Rev. Microbiol.* 2018, 16, 143–155. [CrossRef] [PubMed]

304. Nibbering, B.; Ubags, N.D.J. Microbial interaction in the atopic march. *Clin. Exp. Immunol.* 2020, 199, 12–23. [CrossRef] [PubMed]

305. Pappas, A. Epidermal surface lipids. *Dermatoendocrinology* 2009, 1, 72–76. [CrossRef] [PubMed]

306. Fluhr, J.W.; Kao, J.; Jain, M.; Ahn, S.K.; Feingold, K.R.; Elias, P.M. Generation of free fatty acids from phospholipids regulates stratum corneum acidification and integrity. *J. Investig. Dermatol.* 2001, 117, 44–51. [CrossRef] [PubMed]

307. Diamond, G.; Beckloff, N.; Weinberg, A.; Kisich, K.O. The roles of antimicrobial peptides in innate host defense. *Curr. Pharm. Des.* 2009, 15, 2377–2392. [CrossRef]

308. Das, C.; Olmsted, P.D. The physics of stratum corneum lipid membranes. *Philos. Trans. A Math. Phys. Eng. Sci.* 2016, 374, 20150126. [CrossRef]

309. Stratum Corneum. Wikipedia. Available online: en.wikipedia.org/wiki/Stratum_corneum (accessed on 19 December 2019).

310. Brandner, J.M.; Zorn-Kruppa, M.; Yoshida, T.; Moll, I.; Beck, L.A.; De Benedetto, A. Epidermal tight junctions in health and disease. *Tissue Barriers* 2015, 3, e974451. [CrossRef]

311. Kubo, A.; Nagao, K.; Yokouchi, M.; Sasaki, H.; Amagai, M. External antigen uptake by Langerhans cells with reorganization of epidermal tight junction barriers. *J. Exp. Med.* 2009, 206, 2937–2946. [CrossRef]

312. Addor, F.A. Skin barrier in rosacea. *An. Bras. Dermatol.* 2016, 91, 59–63. [CrossRef]

313. Rocha, M.A.; Bagatin, E. Skin barrier and microbiome in acne. *Arch. Dermatol. Res.* 2018, 310, 181–185. [CrossRef]

314. van der Schaft, J.; Thijs, J.L.; de Bruin-Weller, M.S.; Balak, D.M.W. Dupilumab after the 2017 approval for the treatment of atopic dermatitis, what’s new and what’s next? *Curr. Opin. Allergy Clin. Immunol.* 2019, 19, 341–349. [CrossRef] [PubMed]

315. Jeon, C.; Sekhon, S.; Yan, D.; Afifi, L.; Nakamura, M.; Bhutani, T. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. *Hum. Vaccin. Immunother.* 2017, 13, 2247–2259. [CrossRef] [PubMed]

316. Rivero, A.L.; Whitfeld, M. An update on the treatment of rosacea. *Aust. Prescr.* 2018, 41, 20–24. [CrossRef] [PubMed]

317. Rath, S.K. Acne vulgaris treatment, the current scenario. *Indian J. Dermatol.* 2011, 56, 7–13. [CrossRef]

318. Elias, P.M.; Wakefield, J.S.; Man, M.Q. Moisturizers versus current and next-generation barrier repair therapy for the management of atopic dermatitis. *Ski. Pharmacol. Physiol.* 2019, 32, 1–7. [CrossRef]

319. Man, M.Q.; Hatano, Y.; Lee, S.H.; Man, M.; Chang, S.; Feingold, K.R.; Leung, D.Y.; Hollera, W.; Uchida, Y.; Elias, P.M. Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis, structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. *J. Invest. Dermatol.* 2008, 128, 79–86. [CrossRef]

320. Gupta, M.A.; Gilchrist, B.A. Psychosocial aspects of aging skin. *Dermatol. Clin.* 2005, 23, 643–648. [CrossRef]

321. Amirthalingam, M.; Seetharam, R.N. Stem cell derived cosmetic products, an overview. *Manipal J. Med. Sci.* 2016, 1, 46–52.

322. Lactic Acid. The Environmental Working Group. Available online: www.ewg.org/skindeep/ingredients/703350-LACTIC_ACID (accessed on 20 December 2019).

323. Ammonia. The Environmental Working Group. Available online: www.ewg.org/skindeep/ingredients/700353-AMMONIA (accessed on 20 December 2019).
324. Reiner, A.; Witwer, K.W.; van Balkom, B.W.M.; de Beer, J.; Brondie, C.; Corteling, R.L.; Gabrielson, S.; Gimona, M.; Ibrahim, A.G.; de Kleijn, D.; et al. Concise review, developing best-practice models for the therapeutic use of extracellular vesicles. *Stem Cells Transl. Med.* 2017, 6, 1730–1739. [CrossRef]

325. Ha, D.H.; Kim, S.D.; Cho, B.S.; Lee, J.; Lee, J.H.; Park, S.R.; Youn, J.; Lee, S.H.; Kim, J.E.; Lim, J.; et al. Toxicological evaluation of exosomes derived from human adipose tissue-derived mesenchymal stem/stromal cells. *Regul. Toxicol. Pharmacol.* under review.

326. Maguire, G. The safe and efficacious use of secretome from fibroblasts and adipose-derived (but not bone marrow-derived) mesenchymal stem cells for skin therapeutics. *J. Clin. Aesthet. Dermatol.* 2019, 12, E57–E69. [PubMed]

327. Reza, A.M.M.T.; Choi, Y.J.; Yasuda, H.; Kim, J.O. Human adipose mesenchymal stem cell-derived exosomal-miRNAs are critical factors for inducting anti-proliferation signalling to A2780 and SKOV-3 ovarian cancer cells. *Sci. Rep.* 2016, 6, 38498. [CrossRef] [PubMed]

328. Mesoblast, FDA Agree on Pathway to BLA for Heart Failure Cell Therapy. Genetic Engineering & Biotechnology News. 27 August 2019. Available online: www.genengnews.com/news/mesoblast-fda-agree-on-pathway-to-bla-for-heart-failure-cell-therapy/ (accessed on 13 December 2019).

329. Chen, T.S.; Arslan, F.; Yin, Y.; Tan, S.S.; Lai, R.C.; Choo, A.B.; Padmandabhan, J.; Lee, C.N.; de Kleijn, D.P.; Lim, S.K. Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs. *J. Transl. Med.* 2011, 9, 47. [CrossRef] [PubMed]

330. Lai, R.C.; Yeo, R.W.; Padmanabhan, J.; Choo, A.; de Kleijn, D.P.; Lim, S.K. Isolation and characterization of exosome from human embryonic stem cell-derived c-Myc-immortalized mesenchymal stem cells. *Methods Mol. Biol.* 2016, 1416, 477–494. [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).